Substitute for form 1449A&B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 48

Complete if Known	
Application Number	10/621,254
Filing Date	July 14, 2003
First Named Inventor	Dow, Steven W.
Art Unit	1643
Examiner Name	HOLLERAN, Anne L.
Attorney Docket Number	021819-000300US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-3,906,092	9/1975	Hilleman, et al.	
	AB	US-4,452,775	06/05/1984	Kent	
	AC	US-4,956,296	9/1990	Fahnestock	
	AD	US-4,981,684	01/01/1991	MacKenzie, et al.	
	AE	US-5,023,243	06/11/1991	Tullis	
	AF	US-5,075,109	12/24/1991	Tice, et al.	
	AG	US-5,087,617	02/11/1992	Smith	
	AH	US-5,178,860	01/12/1993	MacKenzie, et al.	
	AI	US-5,234,811	8/1993	Beutler, et al.	
	AJ	US-5,248,670	09/28/1993	Draper, et al.	
	AK	US-5,457,189	10/10/1995	Crooke, et al.	
	AL	US-5,514,577	05/07/1996	Draper, et al.	
	AM	US-5,543,152	08/06/1996	Webb, et al.	
	AN	US-5,663,153	9/1997	Hutcherson, et al.	
	AO	US-5,567,604	10/22/1996	Rando, et al.	
	AP	US-5,576,302	11/19/1996	Cook, et al.	
	AQ	US-5,585,479	12/1996	Hoke, et al.	
	AR	US-5,594,122	01/14/1997	Friesen	
	AS	US-5,595,756	01/21/1997	Bally, et al.	
	AT	US-5,658,891	08/19/1997	Draper, et al.	
	AU	US-5,665,580	09/09/1997	Crooke, et al.	
	AV	US-5,679,354	10/21/1997	Morein, et al.	
	AW	US-5,681,944	10/28/1997	Crooke, et al.	
	AX	US-5,723,335	3/1998	Hutcherson, et al.	
	AY	US-5,736,152	04/07/1998	Dunn	
	AZ	US-5,753,613	05/19/1998	Ansell, et al.	
	BA	US-5,756,097	05/26/1998	Landucci, et al.	
	BB	US-5,766,920	06/16/1998	Babbitt, et al.	
	BC	US-5,780,448	07/14/1998	Davis	
	BD	US-5,785,992	07/28/1998	Ansell, et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 48

Complete if Known	
Application Number	10/621,254
Filing Date	July 14, 2003
First Named Inventor	Dow, Steven W.
Art Unit	1643
Examiner Name	HOLLERAN, Anne L.
Attorney Docket Number	021819-000300US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	BE	US-5,786,189	7/1998	Locht, et al.	
	BF	US-5,804,566	09/08/1998	Carson, et al.	
	BG	US-5,814,335	09/29/1998	Webb, et al.	
	BH	US-5,837,243	11/17/1998	Deo, et al.	
	BI	US-5,843,770	12/01/1998	Ill, et al.	
	BJ	US-5,849,719	12/1998	Carson, et al.	
	BK	US-5,854,418	12/29/1998	Chang, et al.	
	BL	US-5,858,987	01/12/1999	Beer-Romero, et al.	
	BM	US-5,877,309	03/02/1999	McKay, et al.	
	BN	US-5,955,059	09/21/1999	Gilchrest, et al.	
	BO	US-5,965,542	10/12/1999	Wasan, et al.	
	BP	US-5,968,909	10/19/1999	Agrawal, et al.	
	BQ	US-5,985,662	11/16/1999	Anderson, et al.	
	BR	US-5,997,858	12/07/1999	Tovey, et al.	
	BS	US-6,027,726	02/22/2000	Ansell	
	BT	US-6,027,732	02/22/2000	Morein, et al.	
	BU	US-6,030,954	02/29/2000	Wu, et al.	
	BV	US-6,030,955	02/29/2000	Stein, et al.	
	BW	US-6,090,791	07/18/2000	Sato, et al.	
	BX	US-6,107,062	08/22/2000	Hu, et al.	
	BY	US-6,110,745	08/29/2000	Zhang, et al.	
	BZ	US-6,114,167	09/05/2000	Symonds, et al.	
	CA	US-6,121,434	09/19/2000	Peyman, et al.	
	CB	US-6,184,369 B1	02/06/2001	Rando, et al.	
	CC	US-6,207,819 B1	03/27/2001	Manoharan, et al.	
	CD	US-6,214,806 B1	04/10/2001	Krieg, et al.	
	CE	US-6,218,371 B1	04/17/2001	Krieg, et al.	
	CF	US-6,221,882 B1	04/24/2001	Macfarlane	
	CG	US-6,239,116 B1	05/29/2001	Krieg, et al.	
	CH	US-6,348,312	02/19/2002	Peyman, et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 48

Complete if Known	
Application Number	10/621,254
Filing Date	July 14, 2003
First Named Inventor	Dow, Steven W.
Art Unit	1643
Examiner Name	HOLLERAN, Anne L.
Attorney Docket Number	021819-000300US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	CI	US-6,399,630	06/04/2002	Macfarlane	
	CJ	US-6,426,334 B1	07/30/2002	Agrawal, et al.	
	CK	US-6,429,199 B1	08/06/2002	Krieg, et al.	
	CL	US-6,476,000 B1	11/05/2002	Agrawal, et al.	
	CM	US-6,479,504	11/12/2002	Macfarlane, et al.	
	CN	US-6,521,637	02/18/2003	Macfarlane	
	CO	US-6,544,518 B1	04/08/2003	Friede, et al.	
	CP	US-6,558,670 B1	05/06/2003	Friede, et al.	
	CQ	US-6,605,708	08/12/2003	Habus, et al.	
	CR	US-6,610,308	08/26/2003	Haensler	
	CS	US-6,610,661 B1	08/26/2003	Carson, et al.	
	CT	US-6,620,805	09/16/2003	Takle, et al.	
	CU	US-6,653,292 B1	11/25/2003	Krieg, et al.	
	CV	US-6,630,455 B1	10/07/2003	Mitchell	
	CW	US-6,727,230 B1	04/27/2004	Hutcherson, et al.	
	CX	US-6,815,429 B2	11/09/2004	Agrawal	
	CY	US-6,821,957 B1	11/23/2004	Krieg, et al.	
	CZ	US-6,835,395 B1	12/28/2004	Semple, et al.	
	DA	US-6,849,725 B2	02/01/2005	Junghans, et al.	
	DB	US-6,943,240	09/13/2005	Bauer, et al.	
	DC	US-6,949,520	09/27/2005	Hartmann, et al.	
	DD	US-7,001,890	02/26/2006	Wagner, et al.	
	DE	US-7,105,495 B2	09/12/2006	Agrawal, et al.	
	DF	US-7,192,222 B2	10/31/2006	Van Nest, et al.	
	DG	US-2001/0036462 A1	11/01/2001	Fong, et al.	
	DH	US-2002/0009457 A1	01/24/2002	Bowerstock, et al.	
	DI	US-2002/0055477 A1	05/09/2002	Van Nest, et al.	
	DJ	US-2002/0065236 A1	05/30/2002	Yew, et al.	
	DK	US-2002/0091097 A1	07/11/2002	Bratzler, et al.	
	DL	US-2002/0137714 A1	09/26/2002	Kandamilla, et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 4 of 48

Complete if Known	
Application Number	10/621,254
Filing Date	July 14, 2003
First Named Inventor	Dow, Steven W.
Art Unit	1643
Examiner Name	HOLLERAN, Anne L.
Attorney Docket Number	021819-000300US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	DM	US-2002/0164341 A1	11/07/2002	Davis, et al.	
	DN	US-2002/0192184 A1	12/19/2002	Carpentier, et al.	
	DO	US-2003/0022852 A1	01/30/2003	Van Nest, et al.	
	DP	US-2003/0022854 A1	01/30/2003	Dow, et al.	
	DQ	US-2003/0026801 A1	02/06/2003	Weiner, et al.	
	DR	US-2003/0050261 A1	03/13/2003	Krieg, et al.	
	DS	US-2003/0050268 A1	03/13/2003	Krieg, et al.	
	DT	US-2003/0059773 A1	03/27/2003	Van Nest, et al.	
	DU	US-2003/0086900 A1	05/08/2003	Low, et al.	
	DV	US-2003/0091599 A1	05/15/2003	Davis, et al.	
	DW	US-2003/0100527 A1	05/29/2003	Krieg, et al.	
	DX	US-2003/0104044 A1	06/05/2003	Semple, et al.	
	DY	US-2003/0109469 A1	06/12/2003	Carson, et al.	
	DZ	US-2003/0119774 A1	06/26/2003	Foldvari, et al.	
	EA	US-2003/0125279 A1	07/03/2003	Junghans, et al.	
	EB	US-2003/0129251 A1	07/10/2003	Van Nest, et al.	
	EC	US-2003/0139364 A1	07/24/2003	Krieg, et al.	
	ED	US-2003/0148316 A1	08/07/2003	Lipford, et al.	
	EE	US-2003/0148976 A1	08/07/2003	Krieg, et al.	
	EF	US-2003/0165478 A1	09/04/2003	Sokoll, et al.	
	EG	US-2003/0181406 A1	09/25/2003	Schetter, et al.	
	EH	US-2003/0186921 A1	10/02/2003	Carson, et al.	
	EI	US-2003/0191079 A1	10/09/2003	Krieg, et al.	
	EJ	US-2003/0203861 A1	10/30/2003	Carson, et al.	
	EK	US-2003/0212026 A1	11/13/2003	Krieg, et al.	
	EL	US-2003/0224010 A1	12/04/2003	Davis, et al.	
	EM	US-2003/0232074 A1	12/18/2003	Lipford, et al.	
	EN	US-2003/0232780 A1	12/18/2003	Carson, et al.	
	EO	US-2003/0232856 A1	12/18/2003	Macfarlane	
	EP	US-2004/0006010 A1	01/08/2004	Carson, et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 5 of 48

Complete if Known	
Application Number	10/621,254
Filing Date	July 14, 2003
First Named Inventor	Dow, Steven W.
Art Unit	1643
Examiner Name	HOLLERAN, Anne L.
Attorney Docket Number	021819-000300US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	EQ	US-2004/0006034 A1	01/08/2004	Raz, et al.	
	ER	US-2004/0009949 A1	01/15/2004	Krieg	
	ES	US-2004/0013688 A1	01/22/2004	Wise, et al.	
	ET	US-2004/0030118 A1	02/12/2004	Wagner, et al.	
	EU	US-2004/0038922 A1	02/26/2004	Haensler, et al.	
	EV	US-2004/0047869 A1	03/11/2004	Garcon, et al.	
	EW	US-2004/0053880 A1	03/18/2004	Krieg, et al.	
	EX	US-2004/0058883 A1	03/25/2004	Phllips, et al.	
	EY	US-2004/0067902 A9	04/08/2004	Bratzler, et al.	
	EZ	US-2004/0067905 A1	04/08/2004	Krieg, et al.	
	FA	US-2004/0087534 A1	05/06/2004	Krieg, et al.	
	FB	US-2004/0087538 A1	05/06/2004	Krieg, et al.	
	FC	US-2004/0092468 A1	05/13/2004	Schwartz, et al.	
	FD	US-2004/0092472 A1	05/13/2004	Krieg, et al.	
	FE	US-2004/0097719 A1	05/20/2004	Agrawal, et al.	
	FF	US-2004/0106568 A1	06/03/2004	Krieg, et al.	
	FG	US-2004/0131628 A1	07/08/2004	Bratzler, et al.	
	FH	US-2004/0132677 A1	07/08/2004	Fearon, et al.	
	FI	US-2004/0132685 A1	07/08/2004	Krieg, et al.	
	FJ	US-2004/0136948 A1	07/15/2004	Fearon, et al.	
	FK	US-2004/0142469 A1	07/22/2004	Krieg, et al.	
	FL	US-2004/0143112 A1	07/22/2004	Krieg, et al.	
	FM	US-2004/0143112 A1	07/22/2004	Krieg, et al.	
	FN	US-2004/0147468 A1	07/29/2004	Krieg, et al.	
	FO	US-2004/0152649 A1	08/05/2004	Krieg, et al.	
	FP	US-2004/0152656 A1	08/05/2004	Krieg, et al.	
	FQ	US-2004/0152657 A1	08/05/2004	Krieg, et al.	
	FR	US-2004/0157791 A1	08/12/2004	Dow, et al.	
	FS	US-2004/0162258 A1	08/19/2004	Krieg, et al.	
	FT	US-2004/0162262 A1	08/19/2004	Krieg, et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 6 of 48

Complete if Known	
Application Number	10/621,254
Filing Date	July 14, 2003
First Named Inventor	Dow, Steven W.
Art Unit	1643
Examiner Name	HOLLERAN, Anne L.
Attorney Docket Number	021819-000300US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	FU	US-2004/0167089 A1	08/26/2004	Krieg, et al.	
	FV	US-2004/0171150 A1	09/02/2004	Krieg, et al.	
	FW	US-2004/0171571 A1	09/02/2004	Krieg, et al.	
	FX	US-2004/0181045 A1	09/16/2004	Krieg, et al.	
	FY	US-2004/0198680 A1	10/07/2004	Krieg	
	FZ	US-2004/0198688 A1	10/07/2004	Krieg, et al.	
	GA	US-2004/0229835 A1	11/18/2004	Krieg, et al.	
	GB	US-2004/0234512 A1	11/25/2004	Wagner, et al.	
	GC	US-2004/0235770 A1	11/25/2004	Davis, et al.	
	GD	US-2004/0235774 A1	11/25/2004	Davis, et al.	
	GE	US-2004/0235777 A1	11/25/2004	Wagner, et al.	
	GF	US-2004/0235778 A1	11/25/2004	Wagner, et al.	
	GG	US-2004/0248837 A1	12/09/2004	Raz, et al.	
	GH	US-2004/0266719 A1	12/30/2004	McCluskie, et al.	
	GI	US-2005/0004061 A1	01/06/2005	Krieg, et al.	
	GJ	US-2005/0004062 A1	01/06/2005	Krieg, et al.	
	GK	US-2005/0004144 A1	01/06/2005	Carson, et al.	
	GL	US-2005/0009774 A1	01/13/2005	Krieg, et al.	
	GM	US-2005/0013812 A1	01/20/2005	Dow, et al.	
	GN	US-2005/0031638 A1	02/10/2005	Dalemans, et al.	
	GO	US-2005/0032734 A1	02/10/2005	Davis, et al.	
	GP	US-2005/0032736 A1	02/10/2005	Krieg, et al.	
	GQ	US-2005/0037403 A1	02/17/2005	Krieg, et al.	
	GR	US-2005/0037985 A1	02/17/2005	Krieg, et al.	
	GS	US-2005/0043529 A1	02/24/2005	Davis, et al.	
	GT	US-2005/0049215 A1	03/03/2005	Krieg, et al.	
	GU	US-2005/0049216 A1	03/03/2005	Krieg, et al.	
	GV	US-2005/0054601 A1	03/10/2005	Wagner, et al.	
	GW	US-2005/0054602 A1	03/10/2005	Krieg, et al.	
	GX	US-2005/0059619 A1	03/17/2005	Krieg, et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/621,254
				Filing Date	July 14, 2003
				First Named Inventor	Dow, Steven W.
				Art Unit	1643
(Use as many sheets as necessary)				Examiner Name	HOLLERAN, Anne L.
Sheet	7	of	48	Attorney Docket Number	021819-000300US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	GY	US-2005/0059625 A1	03/17/2005	Krieg, et al.	
	GZ	US-2005/0064401 A1	03/24/2005	Olek, et al.	
	HA	US-2005/0070491 A1	03/31/2005	Krieg, et al.	
	HB	US-2005/0075302 A1	04/07/2005	Hutcherson, et al.	
	HC	US-2005/0079152 A1	04/14/2005	Bot, et al.	
	HD	US-2005/0100983 A1	05/12/2005	Bauer, et al.	
	HE	US-2005/0101554 A1	05/12/2005	Krieg, et al.	
	HF	US-2005/0101557 A1	05/12/2005	Krieg, et al.	
	HG	US-2005/0119273 A1	06/02/2005	Lipford, et al.	
	HH	US-2005/0123523 A1	06/09/2005	Krieg, et al.	
	HI	US-2005/0130911 A1	06/16/2005	Uhlmann, et al.	
	HJ	US-2005/0130918 A1	06/16/2005	Agrawal, et al.	
	HK	US-2005/0148537 A1	07/07/2005	Krieg, et al.	
	HL	US-2005/0169888 A1	08/04/2005	Hartman, et al.	
	HM	US-2005/0171047 A1	08/04/2005	Krieg, et al.	
	HN	US-2005/0176672 A1	08/11/2005	Scheule, et al.	
	HO	US-2005/0181035 A1	08/18/2005	Dow, et al.	
	HP	US-2005/0181422 A1	08/18/2005	Bauer, et al.	
	HQ	US-2005/0182017 A1	08/18/2005	Krieg	
	HR	US-2005/0191342 A1	09/01/2005	Tam, et al.	
	HS	US-2005/0197314 A1	09/08/2005	Krieg, et al.	
	HT	US-2005/0209184 A1	09/22/2005	Klinman, et al.	
	HU	US-2005/0214355	09/29/2005	Klinman, et al.	
	HV	US-2005/0215500 A1	09/29/2005	Krieg, et al.	
	HW	US-2005/0215501 A1	09/29/2005	Lipford, et al.	
	HX	US-2005/0233995 A1	10/20/2005	Krieg, et al.	
	HY	US-2005/0233999 A1	10/20/2005	Krieg, et al.	
	HZ	US-2005/0239732 A1	10/27/2005	Krieg, et al.	
	IA	US-2005/0239733 A1	10/27/2005	Jurk, et al.	
	IB	US-2005/0239734 A1	10/27/2005	Uhlmann, et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 8 of 48

Complete if Known	
Application Number	10/621,254
Filing Date	July 14, 2003
First Named Inventor	Dow, Steven W.
Art Unit	1643
Examiner Name	HOLLERAN, Anne L.
Attorney Docket Number	021819-000300US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	IC	US-2005/0239736 A1	10/27/2005	Krieg, et al.	
	ID	US-2005/0244379 A1	11/03/2005	Krieg, et al.	
	IE	US-2005/0244380 A1	11/03/2005	Krieg, et al.	
	IF	US-2005/0245477 A1	11/03/2005	Krieg, et al.	
	IG	US-2005/0249794 A1	11/10/2005	Semple, et al.	
	IH	US-2005/0250726 A1	11/10/2005	Krieg, et al.	
	II	US-2005/0256073 A1	11/17/2005	Lipford, et al.	
	IJ	US-2005/0266015 A1	12/01/2005	Clerici, et al.	
	IK	US-2005/0267057 A1	12/01/2005	Krieg	
	IL	US-2005/0267064 A1	12/01/2005	Krieg, et al.	
	IM	US-2005/0277604 A1	12/15/2005	Krieg, et al.	
	IN	US-2005/0277609 A1	12/15/2005	Krieg, et al.	
	IO	US-2006/0003955 A1	01/05/2006	Krieg, et al.	
	IP	US-2006/0003962 A1	01/05/2005	Ahluwalia, et al.	
	IQ	US-2006/0014713 A1	01/19/2006	Agrawal, et al.	
	IR	US-2006/0019909 A1	01/26/2006	Agrawal, et al.	
	IS	US-2006/0019916 A1	01/26/2006	Agrawal, et al.	
	IT	US-2006/0019923 A1	01/26/2006	Davis, et al.	
	IU	US-2006/0058251 A1	03/16/2006	Krieg, et al.	
	IV	US-2006/0074040 A1	04/06/2006	Kandimalla, et al.	
	IW	US-2006/0089326 A1	04/27/2006	Krieg, et al.	
	IX	US-2006/0094683 A1	05/04/2006	Krieg, et al.	
	IY	US-2006/0140875 A1	06/29/2006	Krieg, et al.	
	IZ	US-2006/0154890 A1	07/13/2006	Bratzler, et al.	
	JA	US-2006/0172966 A1	08/03/2006	Lipford, et al.	
	JB	US-2006/0188913 A1	08/24/2006	Krieg, et al.	
	JC	US-2006/0189550 A1	08/24/2006	Jiang, et al.	
	JD	US-2006/0211639 A1	09/21/2006	Bratzler, et al.	
	JE	US-2006/0211641 A1	09/21/2006	Agrawal, et al.	
	JF	US-2006/0211644 A1	09/21/2006	Krieg, et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 9 of 48

Complete if Known	
Application Number	10/621,254
Filing Date	July 14, 2003
First Named Inventor	Dow, Steven W.
Art Unit	1643
Examiner Name	HOLLERAN, Anne L.
Attorney Docket Number	021819-000300US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number Kind Code[2] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	JG	US-2006/0223769 A1	10/05/2006	Dow, et al.	
	JH	US-2006/0229271 A1	10/12/2006	Krieg, et al.	
	JI	US-2006/0241076 A1	10/26/2006	Uhlmann, et al.	
	JJ	US-2006/0246035 A1	11/02/2006	Ahluwalia, et al.	
	JK	US-2006/0251623 A1	11/09/2006	Bachmann, et al.	
	JL	US-2006/0251677 A1	11/09/2006	Bachmann, et al.	
	JM	US-2006/0286070 A1	12/21/2006	Hartmann, et al.	
	JN	US-			
	JO	US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]	Number[4]	Kind Code[5] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	JP	PCT	WO90/14822	A1	12/13/1990	Northwestern University		
	JQ	PCT	WO91/012811	A1	09/05/1991	Isis Pharmaceuticals, Inc.		
	JR	PCT	WO92/03456	A1	03/05/1992	Isis Pharmaceuticals, Inc.		
	JS	PCT	WO92/18522		10/1992			
	JT	PCT	WO92/21353		12/1992			
	JU	PCT	WO93/25673	A1	12/23/1993	The Regents of the University of California		
	JV	PCT	WO94/04196	A1	03/03/1994	Imperial Cancer Research Technology Limited		
	JW	PCT	WO94/019945	A1	09/15/1994	Isis Pharmaceuticals, Inc.		
	JX	PCT	WO95/05853		03/1995			
	JY	PCT	WO95/17507	A1	06/29/1995	Biognostik Gesellschaft für Biomolekulare Diagnostic MBH [DE]		
	JZ	PCT	WO95/24929	A2	09/21/1995	Brown University Research Foundation		
	KA	PCT	WO95/26204		10/1995			

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 10 of 48

Complete if Known	
Application Number	10/621,254
Filing Date	July 14, 2003
First Named Inventor	Dow, Steven W.
Art Unit	1643
Examiner Name	HOLLERAN, Anne L.
Attorney Docket Number	021819-000300US

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
		Country Code[3]	Number[4]	Kind Code[5] (*if known*)				
	KB	PCT	WO/96/02555	A1	02/01/1996	University of Iowa Research Foundation		☐
	KC	PCT	WO96/02560	A1	02/01/1996	University of North Carolina at Chapel Hill		☐
	KD	PCT	WO96/35782		11/1996			☐
	KE	PCT	WO96/40162	A1	12/19/1996	East Carolina University		☐
	KF	PCT	WO97/03702	A1	02/06/1997	Brown University Research Foundation		☐
	KG	PCT	WO97/28259	A1	08/07/1997	Regents of the University of California		☐
	KH	PCT	WO97/30731	A3	08/28/1997	The Immune Response Corporation		☐
	KI	PCT	WO98/11211	A2	03/19/1998	Hybridon, et al.		☐
	KJ	PCT	WO98/14210	A2	03/19/1998	Hybridon, et al.		☐
	KK	PCT	WO98/16247	A	04/23/1998	Regents of the University of California Regents of the University of California		☐
	KL	PCT	WO98/18810	A1	05/07/1998	University of Iowa Research Foundation		☐
	KM	PCT	WO98/29557	A1	07/09/1998	Biovector Therapeutics		☐
	KN	PCT	WO98/32462	A1	07/30/1998	Wagner, et al.		☐
	KO	PCT	WO98/49288	A1	11/05/1998	Hybridon, et al.		☐
	KP	PCT	WO/98/51278	A2	11/19/1998	INEX Pharmaceuticals Corp.		☐
	KQ	PCT	WO/98/52962	A1	11/26/1998	Merck and Co., Inc.		☐
	KR	PCT	WO/98/55495	A2	12/10/1998	Dynavax Technologies Corp.		☐
	KS	PCT	WO99/30686	A1	06/24/1999	INEX Pharmaceuticals Corp.		☐
	KT	PCT	WO99/33488	A2	07/08/1999	SmithKline Beecham Biologicals S.A.		☐
	KU	PCT	WO99/33493	A1	07/08/1999	INEX Pharmaceuticals Corp.		☐
	KV	PCT	WO99/43350	A1	09/02/1999	IOMAI Corporation		☐
	KW	PCT	WO99/52549	A1	10/29/1999	SmithKline Beecham Biologicals S.A.		☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 11 of 48

Complete if Known	
Application Number	10/621,254
Filing Date	July 14, 2003
First Named Inventor	Dow, Steven W.
Art Unit	1643
Examiner Name	HOLLERAN, Anne L.
Attorney Docket Number	021819-000300US

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
		Country Code[3]	Number[4]	Kind Code[5] (*if known*)				
	KX	PCT	WO99/55743	A1	11/04/1999	INEX Pharmaceuticals Corp.		☐
	KY	PCT	WO99/56755	A1	11/11/1999	University of Iowa Research Foundation		☐
	KZ	PCT	WO99/58118	A2	11/18/1999	CPG Immunopharmaceuticals GMBH		☐
	LA	PCT	WO99/61056	A3	12/02/1999	Loeb Health Research Institute at the Ottawa Hospital		☐
	LB	PCT	WO00/03683	A2	01/27/2000	INEX Pharmaceuticals Corp.		☐
	LC	PCT	WO00/06588	A1	02/10/2000	University of Iowa Research Foundation		☐
	LD	PCT	WO00/15256	A2	03/23/2000	Pasteur Merieux Serums Et Vaccins [FR]		☐
	LE	PCT	WO00/45849	A2	08/10/2000	Genzyme Corporation		☐
	LF	PCT	WO00/46365	A1	08/10/2000	Virginia Commonwealth University		☐
	LG	PCT	WO00/54803	A2	09/21/2000	Panacea Pharmaceuticals, LLC		☐
	LH	PCT	WO00/61151	A2	10/19/2000	The Government of the United States of America		☐
	LI	PCT	WO00/67787	A2	11/16/2000	The Immune Response Corporation		☐
	LJ	PCT	WO00/75304	A1	12/14/2000	Aventis Pasteur [FR]		☐
	LK	PCT	WO01/22972	A2	04/05/2001	Coley Pharmaceuticals, GmbH		☐
	LL	PCT	WO01/35991	A2	05/25/2001	Dynavax Technologies Corp.		☐
	LM	PCT	WO01/45750	A1	06/28/2001	The Regents of the University of California		☐
	LN	PCT	WO01/68143	A2	09/20/2001	Dynavax Technologies Corp.		☐
	LO	PCT	WO01/68144	A2	09/20/2001	Dynavax Technologies Corp.		☐
	LP	PCT	WO01/83503	A2	11/08/2001	Hybridon, Inc.		☐
	LQ	PCT	WO01/85751	A1	11/15/2001	Reliable Pharmaceutical, Inc.		☐
	LR	PCT	WO01/93902	A2	12/13/2001	Biosynexus Incorporated		☐
	LS	PCT	WO02/26757	A2	04/04/2002	Hybridon, Inc.		☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 12 of 48

Complete if Known	
Application Number	10/621,254
Filing Date	July 14, 2003
First Named Inventor	Dow, Steven W.
Art Unit	1643
Examiner Name	HOLLERAN, Anne L.
Attorney Docket Number	021819-000300US

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
		Country Code[3]	Number[4]	Kind Code[5] (*if known*)				
	LT	PCT	WO02/28428	A2	04/11/2002	Aventis Pasteur [FR]		
	LU	PCT	WO02/036767	A3	05/10/2002	INEX Pharmaceuticals Corp.		
	LV	PCT	WO03/000232	A2	01/03/2003	Dynavax Technologies Corp.		
	LW	PCT	WO03/002065	A2	01/09/2003	Chiron Corporation		
	LX	PCT	WO03/024481	A2	03/27/2003	Cytos Biotechnology AG		
	LY	PCT	WO03/026688	A1	04/03/2003	Pharmaderm Laboratories, Ltd.		
	LZ	PCT	WO03/035836	A2	05/01/2003	Hybridon, Inc.		
	MA	PCT	WO03/057822	A3	07/17/2003	Hybridon, Inc.		
	MB	PCT	WO03/066649	A1	08/14/2003	Biomira Inc.		
	MC	PCT	WO03/94963	A2	11/20/2003	INEX Pharmaceuticals Corp.		
	MD	PCT	WO04/007743	A2	01/22/2004	Coley Pharmaceutical GmbH		
	ME	PCT	WO04/026888	A2	04/01/2004	Coley Pharmaceutical GmbH		
	MF	PCT	WO04/041183	A2	05/21/2004	The Regents of the University of California		
	MG	PCT	WO04/058159	A2	07/15/2004	Dynavax Technologies Corp.		
	MH	PCT	WO04/094671	A2	11/04/2004	Coley Pharmaceutical Gmbh		
	MI	PCT	WO05/001055	A2	01/06/2005	Hybridon, Inc.		
	MJ	PCT	WO05/004907	A1	01/20/2005	Cytos Biotechnology AG		
	MK	PCT	WO05/004910	A2	01/20/2005	Intercell Ag		
	ML	PCT	WO05/023289	A1	03/17/2005	Intellectual Property Consulting Incorporated		
	MM	PCT	WO06/002038	A2	01/05/2006	Hybridon, Inc.		
	MN	PCT	WO06/012896	A1	02/09/2006	Universitätsklinikum Schleswig-Holstein		
	MO	PCT	WO06/015872	A1	02/16/2006	Mologen Ag		
	MP	EP	0302758	B1	3/1994			
	MQ	EP	0468520	A3	01/1992			

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/621,254
				Filing Date	July 14, 2003
				First Named Inventor	Dow, Steven W.
				Art Unit	1643
(Use as many sheets as necessary)				Examiner Name	HOLLERAN, Anne L.
Sheet	13	of	48	Attorney Docket Number	021819-000300US

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
		Country Code[3]	Number[4]	Kind Code[5] (*if known*)				
	MR	EP	0773295	A	05/14/1997	Ottawa Civic Hospital		☐
	MS	EP	0092574	A1	04/28/1983	Molecular Biosystems, Inc.		☐
	MT	EP	0819758	A2	01/21/1998	Mixson		☐
	MU	EP	1393745	A1	03/03/2004	Hybridon, Inc.		☐

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	MV	[No author listed] CpG 7909: PF 3512676, PF-3512676. *Drugs R.D.* (2006) 7(5):312-316	☐
	MW	Press Release, Hybridon, Inc. "Hybridon shows immonumodulatory activity of synthetic oligonucleotides", Cambridge, MA, May 7, 2001	☐
	MX	ADYA, N., et al. "Expansion of CREB's DNA recognition specificity by Tax results from interaction with Ala-Ala-Arg at positions 282-284 near the conserved DNA-binding domain of CREB", *Proc Natl Acad Sci USA* (1994) 91(12):5642-5646	☐
	MY	AGRAWAL, S., et al. "Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice", *Proceedings of the National Academy of Sciences* (1991) 88:7595-7599	☐
	MZ	AGRAWAL, S., et al. "Pharmacokinetics of antisense oligonucleotides", *Clin Pharmacokinet* (1995) 28(1):7-16	☐
	NA	AGRAWAL, S., et al. "Medicinal chemistry and therapeutic potential of CpG DNA", *Trends Mol Med.* (2002) 8(3):114-121	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/621,254
				Filing Date	July 14, 2003
				First Named Inventor	Dow, Steven W.
				Art Unit	1643
(Use as many sheets as necessary)				Examiner Name	HOLLERAN, Anne L.
Sheet	14	of	48	Attorney Docket Number	021819-000300US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	NB	AGRAWAL, S., et al. "Novel immunomodulatory oligonucleotides prevent development of allergic airway inflammation and airway hyperresponsiveness in asthma", *Int Immunopharmacol* (2004) 4(1):127-138	☐
	NC	ALPAR, et al. "Potential of particulate carriers for the mucosal delivery of DNA vaccines", *Biochem Soc Trans* (1997) 25(2):337S	☐
	ND	ANFOSSI, et al. HCAPLUS Database, AN: 475562, Abstract. 1989	☐
	NE	ANGIER, N., "Microbe DNA seen as alien by immune system", *New York Times*, April 11, 1995	☐
	NF	ANITESCU, et al. "Interleukin-10 functions in vitro and in vivo to inhibit bacterial DNA-induced secretion of interleukin-12", *J Interferon Cytokine Res.* (1997) 17(12):781-788	☐
	NG	ASKEW, et al. "CpG DNA induces maturation of dendritic cells with distinct effects on nascent and recycling MHC-II antigen-processing mechanisms", *J Immunol.* (2000) 165(12:6889-6895	☐
	NH	AZAD, R.F., et al. "Antiviral Activity of a Phosphorothioate Oligonucleotide Complementary to RNA of the Human Cytomegalovirus Major Immediate-Early Region", *Antimicrobial Agents and Chemotherapy* (1993) 37:1945-1954	☐
	NI	AZUMA, I. "Biochemical and Immunological Studies on Cellular Components of Tubercle Bacilli", *Kekkahu* (1992) 67(9):45-55	☐
	NJ	BARAL, et al. "Immunostimulatory CpG oligonucleotides enhance the immune response of anti-idiotype vaccine that mimics carcinoembryonic antigen", *Cancer Immunol Immunother.* (2003) 52(5):317-327	☐
	NK	BAUER, et al. "DNA activates human immune cells through a CpG sequence-dependent manner", *Immunology* (1999) 97(4):699-705	☐
	NL	BAUER, et al. "Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition", *Proc Natl Acad Sci U S A* (2001) 98(16):9237-9242	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/621,254
				Filing Date	July 14, 2003
				First Named Inventor	Dow, Steven W.
				Art Unit	1643
(Use as many sheets as necessary)				Examiner Name	HOLLERAN, Anne L.
Sheet	15	of	48	Attorney Docket Number	021819-000300US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	NM	BAYEVER, et al. "Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: Initial results of a phase I trial", *Antisense Res Dev.* (1993) 3(4):383-390	☐
	NN	BENNETT, C.F. "Intracellulary Delivery of Oligonucleotides with Cationic Liposomes", *Delivery Strategies for Antisense Oligonucleotide Therapeutics",* (1995) Akthar, Ed.: 223-32 (Abstract)	☐
	NO	BENNETT, R.M., et al. "DNA binding to human leukocytes. Evidence for a receptor-mediated association, internalization, and degredation of DNA", *J Clin Invest* (1985) 76(6):2182-2190	☐
	NP	BIANCO, et al. "Cationic carbon nanotubes bind to CpG oligodeoxynucleotides and enhance their immunostimulatory properties", *J Am Chem Soc.* (2005) 127(1):58-59	☐
	NQ	BIOLABS 1988-1989 Catalog, Random Primer #s 1230, 1601, 1602	☐
	NR	BLAXTER, et al. "Genes expressed in Brugia malayi infective third stage larvae", *Molecular and Biochemical Parasitology* (1996) 77:77-93	☐
	NS	BLAZAR, et al. "Synthetic unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides are potent stimulators of antileukemia responses in naïve and bone marrow transplant recipients", *Blood* (2001) 98(4):1217-1225	☐
	NT	BOGGS, et al. "Characterization and modulation of immune stimulation by modified oligonucleotides", *Antisense Nucleic Acid Drug Dev* (1997) 7(5):461-471	☐
	NU	BOWERSOCK, et al. "Evaluation of an orally administered vaccine, using hydrogels containing bacterial exotoxins of Pasteurella haemolytica, in cattle", *Am J Vet Res* (1994) 55(4):502-509	☐
	NV	BRANDA, R.F., et al. "Immune stimulation by an antisense oligomer complementary to the *rev* gene of HIV-1", *Biochemical Pharmacology* (1993) 45(10):2037-2043	☐
	NW	BRANDA, et al "B-cell proliferation and differentiation in common variable immunodeficiency patients produced by an antisense oligomer to the rev gene of HIV-1", *Clin Immunol Immunopathol* (1996) 79(2):115-121	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/621,254
				Filing Date	July 14, 2003
				First Named Inventor	Dow, Steven W.
				Art Unit	1643
(Use as many sheets as necessary)				Examiner Name	HOLLERAN, Anne L.
Sheet	16	of	48	Attorney Docket Number	021819-000300US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	NX	BRANDA, et al "Amplification of antibody production by phosphorothioate oligodeoxynucleotides", *J Lab Clin Med* (1996) 128(3):329-338	☐
	NY	BRIGNOLE, et al. "Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs", *J Natl Cancer Inst* (2004) 96(15):1171-1180	☐
	NZ	BRISKIN, M., et al. "Lipopolysaccharide - unresponsive mutant pre-B-cell lines blocked in NF-kappa B Activation", *Mol Cell Biol* (1990) 10(1):422-425	☐
	OA	BROIDE, et al. "Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice", *J Immunol.* (1998) 161(12):7054-7062	☐
	OB	BROIDE, et al. "DNA-based immunization for asthma", *Int Arch Allergy Immunol.* (1999) 118(2-4):453-456	☐
	OC	BRUNNER, et al. "Enhanced dendritic cell maturation by TNF-alpha or cytidine-hposphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo", *J Immunol.* (2000) 165(11):6278-6286	☐
	OD	CARPENTIER, et al. "Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs", *Clin Cancer Res.* (2000) 6(6):2469-2473	☐
	OE	CHACE, et al. "Regulation of Differentiation in CD5+ and Conventional B Cells", *Clinical Immunology and Immunopathology* (1993) 68(3):237-332	☐
	OF	CHACE, et al. "Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL-12", *Clin Immunol Immunopathol* (1997) 84(2):185-193	☐
	OG	CHAN, et al. "CpG-A and CpG-B oligodeoxynucleotides differentially affect the cytokine profile, chemokine receptor expression and T-cell priming function of human plasmacytoid dendritic cells", *Blood* (2002) 11:50b. Abstract #3666	☐
	OH	CHANG, Y.N., et al. "The palindromic series I repeats in the simian cytomegalovirus major immediate-early promoter behave as both strong basal enhancers and cyclic AMP response elements", *J Virol* (1990) 64(1):264-277	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/621,254
				Filing Date	July 14, 2003
				First Named Inventor	Dow, Steven W.
				Art Unit	1643
(Use as many sheets as necessary)				Examiner Name	HOLLERAN, Anne L.
Sheet	17	of	48	Attorney Docket Number	021819-000300US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	OI	CHANG, et al. "The effect of CpG-oligodeoxynucletides with different backbone structures and 3' hexameric deoxyriboguanosine run conjugation on the treatment of asthma in mice", *J Allergy Clin Immunol.* (2004) 113(2):S323. Abstract 1196	☐
	OJ	CHATURVERDI, et al. "Stabilization of triple-stranded oligonucleotide complexes: use of probes containing alternating phosphodiester and stereo-uniform cationic phosphoramidate linkages", *Nucleic Acids Res.* (1996) 24(12):2318-2323	☐
	OK	CHEN, et al. "Protective immunity induced by oral immunization with a rotavirus DNA vaccine encapsulated in microparticles", *J. Virol.* (1998) 72(7):5757-5761	☐
	OL	CHOI, et al. "The level of protection against rotavirus shedding in mice following immunization with a chimeric VP6 protein is dependent on the route and the coadministered adjuvant", *Vaccine* (2002) 20(13-14):1733-1740	☐
	OM	CHU, R.S., et al. "CpG oligodeoxynucleotides act as adjuvants that switch on T helper (Th1) immunity", *J Exp Med* (1997) 186(10):1623-1631	☐
	ON	COHEN "Selective anti-gene therapy for cancer: principles and prospects", *Tohoku J Exp Med.* (1992) 168(2):351-359	☐
	OO	COOPER, et al. "Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine", *Vaccine* (2004) 22(23-24):3136-3143	☐
	OP	COSSUM, et al. "Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats", *J Pharmacol Exp Ther* (1993) 267(3):1181-1190	☐
	OQ	COWDERY, et al. "Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides", *J Immunol.* (1996) 156(12):4570-4575	☐
	OR	COWSERT, et al. "In vitro evaluation of phosphorothioate oligonucleotides targeted to the E2 mRNA of papillomavirus: potential treatment for genital warts", *Antimicrob Agents Chemother* (1993) 37(2):171-177	☐
	OS	CROOKE, et al. "Phosphorothioate Oligonucleotides", *Therapeut Apps.* (1995) Ch5:63-84	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 18 of 48

Complete if Known	
Application Number	10/621,254
Filing Date	July 14, 2003
First Named Inventor	Dow, Steven W.
Art Unit	1643
Examiner Name	HOLLERAN, Anne L.
Attorney Docket Number	021819-000300US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	OT	CROSBY, et al. "The Early Responses Gene FGFI-C Encodes a Zinc Finger Transcriptional Activator and is a Member of the GCGGGGGCG (GSG) Element-Binding Protein Family" *Mol. Cell Biol.* (1991) 2:3835-3841	☐
	OU	CRYSTAL "Transfer of Genes to Humans: Early Lessons and Obstacles to Success", *Science* (1995) 270:404-410	☐
	OV	CRYZ, et al. "European Commission COST/STD Initiative. Report of the expert panel VII. Vaccine delivery systems", *Vaccine* (1996) 14(7):665-690	☐
	OW	DAFTARIAN, et al. "Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors", *Cancer Res.* (2004) 64(15):5407-5414	☐
	OX	DAHESHIA, et al. "Immune induction and modulation by topical ocular administration of plasmid DNA encoding antigens and cytokines", *Vaccine* (1998) 16(11-12):1103-1110	☐
	OY	DALPKE, et al. "CpG-DNA as immune response modifier", *Int J Med Microbiol* (2004) 294(5):345-354	☐
	OZ	DASS, et al. "Immunostimulatory activity of cationic-lipid-nucleic-acid complexes against cancer", *J Cancer Res Clin Oncol* (2002) 128(4):177-181	☐
	PA	DAVILA, et al. "Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade", *Cancer Res.* (2003) 63(12):3281-3288	☐
	PB	DAVIS et al. *Journal of Immunology* (1998) 160:870-876	☐
	PC	DAVIS, "Use of CpG DNA for enhancing specific immune responses", *Curr Top Microbiol Immunol.* (2000) 247:171-183	☐
	PD	DAVIS, et al. "CpG ODN is safe and highly effective in humans as adjuvant to HBV vaccine: Preliminary results of Phase I trial with CpG ODN 7909", *Third Annual Conference on Vaccine Res.* (2000) Abstract s25, number 47	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/621,254
				Filing Date	July 14, 2003
				First Named Inventor	Dow, Steven W.
				Art Unit	1643
(Use as many sheets as necessary)				Examiner Name	HOLLERAN, Anne L.
Sheet	19	of	48	Attorney Docket Number	021819-000300US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	PE	DELONG, et al. "Characterization of complexes of oligonucleotides with polyamidoamine starburst dendrimers and effects on intracellular delivery", *J Pharm Sci.* (1997) 86(6):762-764	☐
	PF	DOW, et al. "Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously", *J Immunology* (1999) 163(3):1552-1561	☐
	PG	DRYGA, et al. *Vopr. Virusol.* (41(3):100-104	☐
	PH	ELDRIDGE, et al. "Biodegradable microspheres as a vaccine delivery system", *Mol Immunol.* (1991) 28(3):287-294. Abstract Only	☐
	PI	EMI, et al. "Gene transfer mediated by polyarginine requires a formation of big carrier-complex of DNA aggregate", *Biochem Biophys Res Commun.* (1997) 231(2):421-424	☐
	PJ	ENGLISCH, et al. "Chemically Modified Oligonucleotides as Probes and Inhibitors", *Angew Chem. Int. Ed. Engl.* (1991) 30:613-629	☐
	PK	ERB, K.J., et al. "Infection of mice with *Mycobacterium bovis - Bacillus Calmette-Guerin* (BCG) suppresses allergen-induced airway eosinophilia", *J Exp Med* (1998) 187(4):561-569	☐
	PL	ETLINGER, "Carrier sequence selection - one key to successful vaccines", *Immunology Today* (1992) 13(2):52-55	☐
	PM	FILION, et al. "Major limitations in the use of cationic liposomes for DNA delivery", *Int J Pharmaceut* (1998) 162:159-170	☐
	PN	FOX, R.I. "Mechanism of action of hydroxychloroquine as anantirheumatic drug", *Chemical Abstracts* (1994) 120:15, Abstract No. 182630	☐
	PO	FRALEY, et al. "New generation liposomes: the engineering of an efficient vehicle for intracellular delivery of nucleic acids", *Trends Biochem Sci.* (1981) 6:77-80	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/621,254
				Filing Date	July 14, 2003
				First Named Inventor	Dow, Steven W.
				Art Unit	1643
(Use as many sheets as necessary)				Examiner Name	HOLLERAN, Anne L.
Sheet	20	of	48	Attorney Docket Number	021819-000300US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	PP	FRANCOIS, D.T., et al. "Examination of the inhibitory and stimulatory effects of IFN-α, -β, and -γ on human B-Cell proliferation induced by various B-Cell mitogens", *Clinical Immunology and Immunopathology* (1988) 48:297-306	☐
	PQ	GALLICHAN, et al. "Specific secretory immune responses in the female genital tract following intranasal immunization with a recombinant adenovirus expressing glycoprotein B of herpes simplex virus", *Vaccine* (1995) 13(16)1589-1595	☐
	PR	GALLICHAN, et al. "Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract", *J Immunol.* (2001) 166(5):3451-3457	☐
	PS	GAO, ET AL. "Bacterial DNA and lipopolysaccharide induce synergistic production of TNF-alpha through a post-transcriptional mechanism", *J Immunol.* (2001) 166(11):6855-6860	☐
	PT	GARBI, et al. "CpG motifs as proinflammatory factors render authochthonous tumors permissive for infiltration and destruction", *J Immunol.* (2004) 172(10):5861-5869	☐
	PU	GAREGG, et al. "Nucleoside H-phosphonates. IV. Automated solid phase synthesis of oligoribonucleotides by the hydrogenphosphonate approach", *Tetrahedron Lett.* (1986) 27(34):4055-4058	☐
	PV	GASTON, et al. "CpG methylation has differential effects on the binding of YYI and ETS proteins to the bi-directional promoter of the Surf-1 and Surf-2 genes", *Nucleic Acids Res.* (1995) 23(6):901-909	☐
	PW	GEISSLER, et al. "Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids", *J Immunol* (1997) 158(3):1231-1237	☐
	PX	GOODMAN, et al. "Selective modulation of elements of the immune system by low molecular weight nucleosides", *J Pharmacol Exp Ther.* (1995) 274(3):1552-1557	☐
	PY	GOUTTEFANGEAS, et al. "Problem solving for tumor immunotherapy", *Nat Biotechnol.* (2000) 18(5):491-492	☐
	PZ	GREGORIADIS, et al. "Liposomes for drugs and vaccines", *Trends Biotechnol.* (1985) 3:235-241	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 21 of 48

Complete if Known	
Application Number	10/621,254
Filing Date	July 14, 2003
First Named Inventor	Dow, Steven W.
Art Unit	1643
Examiner Name	HOLLERAN, Anne L.
Attorney Docket Number	021819-000300US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	QA	GREGORIADIS "Ímmunological adjuvants: a role of liposomes", *Immunology Today* (1990) 11(3):89-97	☐
	QB	GREGORIADIS, et al. "Engineering liposomes for drug delivery: progress and problems", *Trends Biotechnol.* (1995) 13(12):527-537	☐
	QC	GROSSMANN, et al. "Avoiding tolerance against prostatic antigens with subdominant peptide epitopes", *J Immunother.* (2001) 24(3):237-241	☐
	QD	GURA, T., "Antisense has growing pains", *Science* (1995) 270:575-576	☐
	QE	GURSEL, et al. "Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide", *J Leukoc Biol.* (2002) 71(5):813-820	☐
	QF	GURSEL, et al. "Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides", *J Immunol.* (2001) 167(6):3324-3328	☐
	QG	HADDEN, et al. "Immunostimulants", *Trends Pharmacol Sci.* (1993) 141:169-174	☐
	QH	HADDEN, et al. "Immunopharmacology", *JAMA* (1992) 268(20):2964-2969	☐
	QI	HAFNER, et al."Antimetastatic effect of CpG DNA mediated by type I IFN", *Cancer Res.* (2001) 61(14):5523-5528	☐
	QJ	HAHM, et al. "Efficacy of polyadenylic.polyuridylic acid in the treatment of chronic active hepatitis B", *Int J Immunopharmacol.* (1994) 16(3):217-225	☐
	QK	HALPERN, et al. "Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha", *Cell Immunol.* (1996) 167(1):72-78	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/621,254
				Filing Date	July 14, 2003
				First Named Inventor	Dow, Steven W.
				Art Unit	1643
(Use as many sheets as necessary)				Examiner Name	HOLLERAN, Anne L.
Sheet	22	of	48	Attorney Docket Number	021819-000300US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	QL	HANEBERG, et al. "Induction of specific immunoglobulin A in the small intestine, colon-rectum, and vagina measured by a new method for collection of secretions from local mucosal surfaces", *Infect. Immun.* 62(1):15-23	☐
	QM	HARRINGTON, et al. "Adjuvant effects of low doses of a nuclease-resistant derivative of polyinosinic acid . polycytidylic acid on antibody responses of monkeys to inactivated Venezuelan equine encephalomyelitis virus vaccine", *Infect Immun.* (1979) 24(1):160-166	☐
	QN	HARTMANN, et al. "CpG DNA and LPS induce distinct patterns of activation in human monocytes", *Gene Ther.* (1999) 6(5):893-903	☐
	QO	HARTMANN, et al. "Mechanism and function of a newly identified CpG DNA motif in human primary B cells", *J. Immunol* (2000) 164(2):944-953	☐
	QP	HARTMANN, et al. "Spontaneous and cationic lipid-mediated uptake of antisense oligonucleotides in human monocytes and lymphocytes", *J Pharmacol Exp Ther.* (1998) 285(2):920-928	☐
	QQ	HARTMANN, et al. "Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo", *J Immunol.* (2000) 164(3):1617-1624	☐
	QR	HARTMANN, et al. "CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells", *Proc Natl Acad Sci USA* (1999) 96(16):9305-9310	☐
	QS	HATZFELD, J., et al. "Release of Early Human Hematopoietic Progenitors from Quiescence by Antisense Transforming Growth Factor β1 or Rb Oligonucleotides", *J. Exp. Med.,* (1991) 174:925-929	☐
	QT	HAYNES, et al. "Particle-mediated nucleic acid immunization", *J Biotechnol.* (1996) 44(1-3):37-42	☐
	QU	HECKELSMILLER, et al. "Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model", *J Immunol.* (2002) 169(7):3892-3899	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/621,254
				Filing Date	July 14, 2003
				First Named Inventor	Dow, Steven W.
				Art Unit	1643
(Use as many sheets as necessary)				Examiner Name	HOLLERAN, Anne L.
Sheet	23	of	48	Attorney Docket Number	021819-000300US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	QV	HEEG, et al. "CpG DNA as a Th1 trigger", *Int Arch Allergy Immunol.* (2000) 121(2):87-97	☐
	QW	HENRY, et al. "Chemically modified oligonucleotides exhibit decreased immune stimulation in mice", *J Pharmcol Exp Ther.* (2000) 292(2):468-479	☐
	QX	HIGHFIELD, P.E., "Sepsis: the More, the Murkier", *Biotechnology* (1994) 12:828	☐
	QY	HIGAKI, et al. "Mechanisms involved in the inhibition of growth of a human B lymphoma cell line B104, by anti-MHC class II antibodies", *Immunol Cell Biol.* (1994) 72(3):205-214	☐
	QZ	HINKULA, et al. "Recognition of prominent viral epitopes induced by immunization with human immunodeficiency virus type I regulatory genes", *J Virol* (1997) 71(7):5528-5539	☐
	RA	HOEFFLER, J.P., et al. "Identification of multiple nuclear factors that interact with cyclic adenosine 3',5'-monophosphate response element-binding protein and activating transcription factor-2 by protein-protein interactions", *Mol Endocrinol* (1991) 5(2):256-266	☐
	RB	HOPKIN, et al. "Curbing the CpGs of Bacterial and Viral DNA", *BioMedNet.* (1999) June 25; Issue 57	☐
	RC	HSU, *Nature Med.* (1996) 2(5):540-544	☐
	RD	HUANG, et al. "Induction and regulation of Th1-inducing cytokines by bacterial DNA, lipopolysaccharide, and heat-inactivated bacteria", *Infect Immun.* (1999) 67(12):6257-6263	☐
	RE	HUDSON, et al. "Nucleic acid dendrimers: Novel biopolymer structures", *J Am Chem Soc.* (1993) 115:2119-2124	☐
	RF	HUNTER, et al. "Biodegradable microspheres containing grouop B-Streptococcus vaccine: immune response in mice", *Am J Obstet Gynecol.* (2001) 185(5):1174-1179	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/621,254
				Filing Date	July 14, 2003
				First Named Inventor	Dow, Steven W.
				Art Unit	1643
(Use as many sheets as necessary)				Examiner Name	HOLLERAN, Anne L.
Sheet	24	of	48	Attorney Docket Number	021819-000300US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	RG	IGUCHI-ARIGA, S.M., et al. "CpG methylation of the cAMP -responsive enhance/promoter sequence TGACGTCA abolishes specific factor binding protein and as well as transcriptional activation", *Genes Dev* (1989) 3(5):612-619	☐
	RH	IHO, et al. "Oligodeoxynucleotides containing palindrome sequences with internal 5'-CpG-3' act directly on human NK and activated T cells to induce IFN-gamma production in vitro", *J Immunol.* (1999) 163(7):3642-3652	☐
	RI	IOANNOU, et al. "The immunogenicity and protective efficacy of bovine herpesvirus 1 glycoprotein D plus Emulsigen are increased by formulation with CpG oligodeoxy nucleotides", *J Virol.* (2002) 76(18):9002-9010	☐
	RJ	International Search Report for PCT/US95/01570 (July 5, 1995)	☐
	RK	ISHIKAWA, R., et al. "IFN induction and associated changes in splenic leukocyte distribution", *J Immunol* (1993) 150(9):3713-3727	☐
	RL	IVERSON, et al. "In vivo studies with phosphorothioate oligonucleotides: pharmacokinetics prologue", *Anticancer Drug Des.* (1991) 6(6):531-538	☐
	RM	IVERSON, et al. "Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type I in the adult male rat following single injections and continuous infusion", *Antisense Res Dev.* (1994) 4(1):43-52	☐
	RN	JACOBSON, et al. "Early viral response and on treatment response to CpG 10101 (ACTILON™), in combination with pegylated interferon and/or ribavirin, in chronic HCV genotype 1 infected patients with prior relapse response. 57th Annual Meeting of American Association for the Study of the Liver Diseases (AASLDL). 2006 Oct 30. Boston, Mass; presented Abstract #96	☐
	RO	JAKOB, et al. "Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA", *J Immunol.* (1998) 161(6):3042-3049	☐
	RP	JAKOB, et al. "Bacterial DNA and CpG-containing oligodeoxynucleotides activate cutaneous dendritic cells and induce IL-12 production: implications for the augmentation of Th1 responses", *Int Arch Allergy Immunol* (1999) 118(2-4):457-461	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/621,254
				Filing Date	July 14, 2003
				First Named Inventor	Dow, Steven W.
				Art Unit	1643
(Use as many sheets as necessary)				Examiner Name	HOLLERAN, Anne L.
Sheet	25	of	48	Attorney Docket Number	021819-000300US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	RQ	JAKWAY, J., et al. "Growth regulation of the B lymphoma cell line WEHI-231 by anti-immunoglobulin, lipopolysaccharide, and other bacterial products", *J. Immunol* (1996) 137(7):2225-2231	☐
	RR	JAROSZEWSKI, J., et al. "Cellular uptake of antisense oligonucleotides", *Adv Drug Delivery Rev* (1991) 6(3):235-250	☐
	RS	JASHKE, et al. "Automated incorporation of polyethylene glycol into synthetic oligonucleotides", *Tetrahedron Lett.* (1993) 34(2):301-304	☐
	RT	JIANG, et al. "Enhancing Immunogenicity by CpG DNA", *Curr Opin Mol Ther.* (2003) 5(2):180-185	☐
	RU	JIAO, et al. "Enhanced hepatitis C virus NS3 specific Th1 immune responses induced by co-delivery of protein antigen and CpG with cationic liposomes", *J Gen Virol* (2004) 85(Pt 6):1545-1553	☐
	RV	JOHNSON, et al. "Non-specific resistance against microbial infections induced by polyribonucleotide complexes. In: Immunopharmacology of infection diseases: Vaccine adjuvants and modulators of non-specific resistance (1987) 291-301	☐
	RW	JUFFERMANS, et al. "CpG oligodeoxynucleotides enhance host defense during murine tuberculosis", *Infect Immun* (2002) 70(1):147-152	☐
	RX	KANDIMALLA, et al. "A dinucleotide motif in oligonucleotides shows potent immunomodulatory activity and overrides species-specific recognition observed with CpG motif", *Proc Natl Acad Sci USA* (2003) 100(24):14303-14308	☐
	RY	KANDIMALLA, et al. "Effect of chemical modifications of cytosine and guanine in a CpG-motif of oligonucleotides: structure-immunostimulatory activity relationships", *Bioorg Med Chem* (2001) 9(3):807-813	☐
	RZ	KANDIMALLA, et al. "Towards optimal design of second-generation immunomodulatory oligonucleotides", *Curr Opin Mol Ther* (2002) 4(2):122-129	☐
	SA	KANDIMALLA, et al. "Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles", *Nucleic Acids Res* (2003) 31(9):2393-2400	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/621,254
				Filing Date	July 14, 2003
				First Named Inventor	Dow, Steven W.
				Art Unit	1643
(Use as many sheets as necessary)				Examiner Name	HOLLERAN, Anne L.
Sheet	26	of	48	Attorney Docket Number	021819-000300US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	SB	KATAOKA, T., et al. "Immunotherapeutic potential in guinea-pig tumor model of deoxyribonucleic acid from Mycobacterium bovis BCG complexed with poly-L-lysine and carboxymethylcellulose", *Jpn J Med Sci Biol* (1990) 43(5):171-182	☐
	SC	KATAOKA, T., et al. "Antitumor activity of synthetic oligonucleotides with sequences from cDNA encoding proteins of *Mycobacterium bovis* BCG", *Japanese Journal of Cancer Research* (1992) 83:244-247	☐
	SD	KIMURA, Y,. et al. "Binding of Oligoguanylate to Scavenger Receptors is Required for Oligonucleotides to Augment NK Cell Activity and Induce IFN", *J. Biochem* (1994) 116(5):991-994	☐
	SE	KLINE, J. N., et al. "CpG motif oligonucleotides are effective in prevention of eosinophilic inflammation in a murine model of asthma", *J Invest Med* (1996) 44(7):380A	☐
	SF	KLINE, J. N., et al. "CpG oligonucleotides can reverse as well as prevent TH2-mediated inflammation in a murine model of asthma", *J Invest Med* (1997) 45(7):298A	☐
	SG	KLINE, J. N., et al. "Immune redirection by CpG oligonucleotides. Conversion of a Th2 response to a Th1 response in a murine model of asthma", *J Invest Med.* (1997) 45(3):282A	☐
	SH	KLINE, et al. "Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma", *J Immunol.* (1998) 160(6):2555-2559	☐
	SI	KLINMAN, DM., et al. "CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma", *Proc Natl Acad Sci USA* (1996) 93(7):2879-2883	☐
	SJ	KLINMAN, et al. "Contribution of CpG motifs to the immunogenicity of DNA vaccines", *J Immunol.* (1997) 158(8):3635-3639	☐
	SK	KLINMAN, et al. "Immune recognition of foreign DNA: a cure for bioterrorism?" *Immunity* (1999) 11(2):123-129	☐
	SL	KLINMAN, et al. "Immunotherapeutic applications of CpG-containing oligodeoxynucleotides", *Drug News Perspect.* (2000) 13(5):289-296	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/621,254
				Filing Date	July 14, 2003
				First Named Inventor	Dow, Steven W.
				Art Unit	1643
(Use as many sheets as necessary)				Examiner Name	HOLLERAN, Anne L.
Sheet	27	of	48	Attorney Docket Number	021819-000300US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	SM	KLINMAN, et al "Immunotherapeutic uses of CpG oligodeoxynucleotides", *Nat Rev Immunol* (2004) 4(4):249-258	☐
	SN	KNIPE, et al., eds., *Fields' Virology* (2001)1:1004-1016	☐
	SO	KNIPE, et al., eds., *Fields' Virology* (2001)1:1564	☐
	SP	KOVARIK, et al. "CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming", *J. Immunol* (1999) 162(3):1611-1617	☐
	SQ	KRANZER, et al. "CpG-oligodeoxynucleotides enhance T-cell receptor-triggered interferon-gamma production and up-regulation of CD69 via induction of antigen-presenting cell-derived interferon type 1 and interleukin-12." *Immunology* (2000) 99(2):170-178	☐
	SR	KRIEG, et al. "A role for endogenous retroviral sequences in the regulation of lymphocyte activation", *J Immunol.* (1989) 143(8):2448-2451	☐
	SS	KRIEG, et al. "A role for endogenous retroviral sequences in the regulation of lymphocyte activation", *J Immunol.* (1989) 143(8):2448-2451	☐
	ST	KRIEG, et al. "Uptake of oligodeoxyribonucleotides by lymphoid cells is heterogeneous and inducible", *Antisense Res Dev* (1991) 1(2):161-171	☐
	SU	KRIEG, et al. "Modification of antisense phosphodiester oligodeoxynucleotides by a 5' cholesteryl moiety increases cellular association and improves efficacy", *Proc Natl Acad Sci USA* (1993) 90(3):1048-1052	☐
	SV	KRIEG, et al. "Lymphocyte activation mediated by oligodeoxynucleotides or DNA containing novel un-methylated CpG motifs", American College of Rheumatology 58th National Scientific Meeting. Minneapolis, MN, October 22, 1994. Abstracts. *Arthritis Rheum.* (1994) 37(9 Suppl).	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/621,254
				Filing Date	July 14, 2003
				First Named Inventor	Dow, Steven W.
				Art Unit	1643
(Use as many sheets as necessary)				Examiner Name	HOLLERAN, Anne L.
Sheet	28	of	48	Attorney Docket Number	021819-000300US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	SW	KRIEG, et al. "Phosphorothioate oligodeoxynucleotides: antisense or anti-protein?", *Antisense Res Dev.* (1995) 5(4):241	☐
	SX	KRIEG "CpG DNA: a pathogenic factor in systemic lupus erythematosus? *J Clin Immunol* (1995) 15(6):284-292	☐
	SY	KRIEG, et al. "Infection", in McGraw Hill Book. (1996) pp. 242-243	☐
	SZ	KRIEG, et al. "Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs", *Antisense Nucleic Acid Drug Dev* (1996) 6(2):133-139	☐
	TA	KRIEG, et al. "An innate immune defense mechanism based on the recognition of CpG motifs in microbial DNA", *J Lab Clin Med* (1996) 128(2):128-133	☐
	TB	KRIEG, et al. "Bacterial DNA or oligonucleotides containing CpG motifs protect mice from lethal L. monocytogenes challenge", *1996 Meeting on Molecular Approaches to the Control of Infectious Diseases*, Cold Spring Harbor Laboratory, (1996): 116	☐
	TC	KRIEG, et al. "Unmethylated CpG DNA protects mice from lethal listeria monocytogenes challenge", *Vaccines* (1997) 97:77-79	☐
	TD	KRIEG, et al. "Leukocyte stimulation by oligodeoxynucleotides", *Applied Antisense Oligonucleotide Technology* (1998) pp. 431-448	☐
	TE	KRIEG, et al. "The role of CpG dinucleotides in DNA vaccines", *Trends in Microbiology* (1998) 6(1):23-27	☐
	TF	KRIEG, et al. "Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs", *Proc Natl Acad Sci USA* (1998) 95(21):12631-12636	☐
	TG	KRIEG, et al. "The CpG motif: Implications for clinical immunology", *BioDrugs* (1998) 10(5):341-346	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/621,254
				Filing Date	July 14, 2003
				First Named Inventor	Dow, Steven W.
				Art Unit	1643
(Use as many sheets as necessary)				Examiner Name	HOLLERAN, Anne L.
Sheet	29	of	48	Attorney Docket Number	021819-000300US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	TH	KRIEG, et al. Chapter 8: "Immune Stimulation by Oligonucleotides" in: *Antisense Research and Application*, Crooke, editor, (1998) pp. 243-262	☐
	TI	KRIEG, et al. "CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge", *J Immunol.* (1998) 161(5):2428-2434	☐
	TJ	KRIEG, et al. "Direct immunologic activities of CpG DNA and implications for gene therapy", *J Gene Med.* (1999) 1(1):56-63	☐
	TK	KRIEG, et al. "Mechanisms and applications of immune stimulatory CpG oligodeoxy nucleotides", *Biochim Biophys Acta* (1999) 1489(1):107-116	☐
	TL	KRIEG, et al. "Applications of immune stimulatory CpG DNA for antigen-specific and antigen-non-specific cancer immunotherapy", *Eur J Canc.* (1999) 35/Suppl4:S10. Abstract #14	☐
	TM	KRIEG, et al. "How to exclude immunostimulatory and other nonantisense effects of antisense oligonucleotides", *Manual of Antisense* (1999) pp. 79-89	☐
	TN	KRIEG, et al. "Mechanisms and therapeutic applications of immune stimulatory CpG DNA", *Pharmacol Ther.* (1999) 84(2):113-120	☐
	TO	KRIEG, et al. "CpG DNA: a novel immunomodulator", *Trends Microbiol.* (1999) 7(2):64-65	☐
	TP	KRIEG, et al. "The role of CpG motifs in innate immunity", *Curr Opin Immunol.* (2000) 12(1):35-43	☐
	TQ	KRIEG, et al. "Signal transduction induced by immunostimulatory CpG DNA", *Springer Semin Immunopathol* (2000) 22(1-2):97-105	☐
	TR	KRIEG, et al. "Rescue of B cells from apoptosis by immune stimulatory CpG DNA", *Springer Semin Immunopathol.* (2000) 22(1-2):55-61	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/621,254
				Filing Date	July 14, 2003
				First Named Inventor	Dow, Steven W.
				Art Unit	1643
(Use as many sheets as necessary)				Examiner Name	HOLLERAN, Anne L.
Sheet	30	of	48	Attorney Docket Number	021819-000300US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	TS	KRIEG, et al. "Mechanism of action of CpG DNA", *Curr Top Microbiol Immunol* (2000) 247:1-21	☐
	TT	KRIEG, et al. "Rescue of B cells from apoptosis by immune stimulatory CpG DNA", *Springer Semin Immunopathol.* (2000) 22(1-2):55-61	☐
	TU	KRIEG, et al. "Immune effects and therapeutic applications of CpG motifs in bacterial DNA", *Immunopharmacology* (2000) 48(3):303-305	☐
	TV	KRIEG, et al. "Causing a commotion in the blood: immunotherapy progresses from bacteria to bacterial DNA" *Immuol Today* (2000) 21(10):521-526	☐
	TW	KRIEG, et al. "Now I know my CpGs", *Trends Microbiol.* (2001) 9(6):249-252	☐
	TX	KRIEG, et al. "Enhancing vaccines with immune stimulatory CpG DNA", *Curr Opin Mol Ther.* (2001) 3(1):15-24	☐
	TY	KRIEG, et al. Chapter 7: "CpG oligonucleotides as immune adjuvants", *Ernst Schering Research Found Workshop* (2001) 30:105-118	☐
	TZ	KRIEG, et al. "Immune effects and mechanisms of action of CpG motifs", *Vaccine* (2001) 129(6):618-622	☐
	UA	KRIEG, et al. Chapter 17: Immune stimulation by oligonucletides", *Antisense Drug Tech.* (2001) 1394:471-515	☐
	UB	KRIEG, et al. "CpG motifs in bacterial DNA and their immune effects", *Annu Rev Immunol.* (2002) 20:709-760	☐
	UC	KRIEG, et al. "Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodoexynucleotide TLR9 agonist", *J Immunother* (2004) 27(6):460-471	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/621,254
				Filing Date	July 14, 2003
				First Named Inventor	Dow, Steven W.
				Art Unit	1643
(Use as many sheets as necessary)				Examiner Name	HOLLERAN, Anne L.
Sheet	31	of	48	Attorney Docket Number	021819-000300US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	UD	KRIEG, et al. "P-chirality-dependent immune activation by phosphorothioate CpG oligodeoxynucleotides", *Oligonucleotides* (2003) 13(6):491-499	☐
	UE	KRIEG, et al. "Therapeutic potential of Toll-like receptor 9 activation", *Nat Rev Drug Discov* (2006) 5(6):471-484	☐
	UF	KRIEG, et al. "Antiinfective applications of toll-like receptor 9 agonists", *Proc. Am Thorac Soc.* (2007) 4(3):289-294	☐
	UG	KUBY, *Immunology*, (1994) Chapter 13	☐
	UH	KUKOWSKA-LATALLO, et al. "Efficient transfer of genetic material into mammalian cells using Starburst polyamidoamine dendrimers", *Proc Natl Acad Sci USA* (1996) 93(10)4897-4902	☐
	UI	KURAMOTO, et al. "In situ infiltration of natural killer-like cells induced by intradermal injection of the nucleic acid fraction from BCG", *Microbiol Immunol* (1989) 33(11):929-940	☐
	UJ	KURAMOTO, et al. "Induction of T-cell-mediated immunity against MethA fibrosarcoma by intratumoral injections of a bacillus Calmette-Guerin nucleic acid fraction", *Cancer Immunol Immunother.* (1992) 34(5):283-288	☐
	UK	KURAMOTO, et al. "Changes of host cell infiltration into Meth A fibrosarcoma tumor during the course of regression induced by injections of a BCG nucleic acid fraction", *Int J Immunopharmacol.* (1992) 14(5):773-782	☐
	UL	KURAMOTO, et al. "Oligonucleotide Sequences Required for Natural Killer Cell Activation", *Jpn. J. Cancer Res* (1992) 83:1128-1131	☐
	UM	LEDERMAN, et al. "Polydeoxyguanine motifs in a 12-mer phosphorothioate oligodeoxynucleotide augment binding to the v3 loop of HIV-1 gp120 and potency of HIV-1 inhibition independency of G-tetrad formation", *Antisense Nucleic Acid Drug Dev.* (1996) 6(4):281-289	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/621,254
				Filing Date	July 14, 2003
				First Named Inventor	Dow, Steven W.
				Art Unit	1643
(Use as many sheets as necessary)				Examiner Name	HOLLERAN, Anne L.
Sheet	32	of	48	Attorney Docket Number	021819-000300US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	UN	LEE, et al. "Immuno-stimulatory effects of bacterial-derived plasmids depend on the nature of the antigen in intramuscular DNA inoculations", *Immunology* (1998) 94(3):285-289	☐
	UO	LEIBSON, et al. "Role of gamma-interferon in antibody-producing responses", *Nature* (1984) 4:309(5971):799-801	☐
	UP	LEONARD, et al. "Conformation of Guanine 8-Oxoadenine Base Pairs in the Crystal Structure of d(CGCGAATT(08A)GCG):", *Biochemistry* (1992) 31(36):8415-8420	☐
	UQ	LETSINGER, et al. "Cholesteryl-conjugated oligonucleotides: synthesis, properties, and activity as inhibitors of replication of human immunodeficiency virus in cell culture", *Proc Natl Acad Sci USA* (1989) 86(17):6553-6556	☐
	UR	LETSINGER, et al. "Synthesis and properties of modified oligonucleotides", *Nucleic Acids Symp Ser.* (1991) 24:75-78	☐
	US	LI, et al. "Enhanced immune response to T-independent antigen by using CpG oligodeoxynucleotides encapsulated in liposomes", *Vaccine* (2001) 20(1-2):148-157	☐
	UT	LIPFORD, et al. "CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants", *Eur J. Immunol* (1997) 27(9):2340-2344	☐
	UU	LIPFORD, et al. "Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines", *Eur J Immunol* (1997) 27(12):3420-3426	☐
	UV	LIPFORD, et al. "Bacterial DNA as immune cell activator", *Trends Microbiol* (1998) 6(12):496-500	☐
	UW	LITZINGER, et al. "Fate of cationic liposomes and their complex with oligonucleotide in vivo", *Biochim Biophys Acta"*, (1996) 1281(2):139-149	☐
	UX	LIU, et al. "Recombinant interleukin-6-protects mice against experimental bacterial infection", *Infect Immun.* (1992) 60(10):4402-4406	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/621,254
				Filing Date	July 14, 2003
				First Named Inventor	Dow, Steven W.
				Art Unit	1643
(Use as many sheets as necessary)				Examiner Name	HOLLERAN, Anne L.
Sheet	33	of	48	Attorney Docket Number	021819-000300US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	UY	LIU, et al. "CpG ODN is an effective adjuvant in immunization with tumor antigen", *J Invest Med.* (1997) 45(7):333A	☐
	UZ	LOKE, et al. "Delivery of c-myc antisense phosphorothioate oligodeoxynucleotides to hematopoietic cells in culture by liposome fusion: specific reduction in c-myc protein expression correlates with inhibition of cell growth and DNA synthesis", *Curr Top Microbiol Immunol.* (1988) 141:282-289	☐
	VA	LONDSORF, et al. "Intratumor CpG-oligodeoxynucleotide injection induces protective antitumor T cell immunity", *J Immunol.* (2003) 171(8):3941-3946	☐
	VB	MacFARLANE, et al. "Unmethylated CpG-containing oligodeoxynucleotides inhibit apoptosis in WEHI 231 B lymphocytes induced by several agents: evidence for blockade of apoptosis at a distal signaling step" *Immunology* (1997) 91(4):586-593	☐
	VC	MacFARLANE, et al. "Antagonism of immuno-stimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds", *J. Immunol* (1998) 160(3):1122-1131	☐
	VD	MACKELLAR, et al. "Synthesis and physical properties of anti-HIV antisense oligonucleotides bearing terminal lipophilic groups", *Nucleic Acids Res.* (1992) 20(13):3411-3417	☐
	VE	MAGNUSSON, et al. "Importance of CpG dinucleotides in activation of natural IFN-alpha-producing cells by a lupus -related oligodeoxynucleotide", *Scand J Immunol.* (2001) 54(6):543-550	☐
	VF	MAJOR, et al. "Chapter 34 Hepatitis C Virus" in *Fields' Virology* (2001) 1:1127-1161	☐
	VG	MALOY, et al. "Induction of Th1 and Th2 CD4+ T cell responses by oral or parenteral immunization with ISCOMS", *Eur J Immunol* (1995) 25(10):2834-2841	☐
	VH	MALTESE, et al. "Sequence context of antisense RelA/NF-kappa B phosphorothioates determines specificity", *Nucleic Acids Res* (1995) 23(7):1146-1151	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				*Application Number*	10/621,254
				Filing Date	July 14, 2003
				First Named Inventor	Dow, Steven W.
				Art Unit	1643
(Use as many sheets as necessary)				*Examiner Name*	HOLLERAN, Anne L.
Sheet	34	of	48	*Attorney Docket Number*	021819-000300US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	VI	MANCILLA-RAMIREZ, et al. "[Phosphatidycholine induces an increase in the production of interleukin-6 and improves survival of rats with neonatal sepsis caused by Klebsiella pneumoniae] *Gac Med Mex* (1995) 131(1):14-22	☐
	VJ	MANEGOLD, et al. "Addition of PF-3512676 (CpG 7909) to a taxane/platinum regimen for first line treatment of unresectable non-small cell lung cancer (NSCLC) improves objective response-Phase II clinical trial", *Pfizer Poster* (2005) Abstract 1131	☐
	VK	MARTIN-OROZCO, et al. "Enhancement of antigen-presenting cell surface molecules involved in cognate interactions by immunostimulatory DNA sequences", *Int Immunol* (1999) 11(7):1111-1118	☐
	VL	MASTRANGELO, et al. *Seminars in Oniology* (1996) 23(1):4-21	☐
	VM	MATSON, S., et al. "Nonspecific suppression of [3H] thymidine incorporation by "control" oligonucleotides", *Antisense Res Dev* (1992) 2(4):325-330	☐
	VN	MATSUKURA, et al. "Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (arts/trs) in chronically infected cells", *Proc Natl Acad Sci USA* (1989) 86(11):4244-4248	☐
	VO	McCLUSKIE, et al. "CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice", *J Immunol.* (1998) 161(9):4463-4466	☐
	VP	McCLUSKIE, et al. "CpG DNA as mucosal adjuvant" *Vaccine* (2000) 18:231-237	☐
	VQ	McCLUSKIE, et al. "Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants", *Vaccine* (2001) 19(4-5):413-422	☐
	VR	McCLUSKIE, et al. "CpG DNA is an effective oral adjuvant to protein antigens in mice", *Vaccine* (2001) 19(7-8):950-957	☐
	VS	McCLUSKIE, et al. "Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates", *Mol Med.* (1999) 5(5):287-300	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/621,254
				Filing Date	July 14, 2003
				First Named Inventor	Dow, Steven W.
				Art Unit	1643
(Use as many sheets as necessary)				Examiner Name	HOLLERAN, Anne L.
Sheet	35	of	48	Attorney Docket Number	021819-000300US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	VT	McCLUSKIE, et al. "The use of CpG DNA as a mucosal vaccine adjuvant", *Curr Opin Investig Drugs* (2001) 2(1):35-39	☐
	VU	McCLUSKIE *Vaccine* (2001) 19:3759-3768	☐
	VV	McCLUSKIE , et al. "Mucosal immunization of mice using CpG DNA and/or mutants of the heat-labile enterotoxin of Escherichia coli as adjuvants", *Vaccine* (2001) 273:352-354	☐
	VW	McCLUSKIE, et al. "Intranasal immunization of mice with CpG DNA induces strong systemic and mucosal responses that are influenced by other mucosal adjuvants and antigen distribution", *Mol Med* (2000) 6(10):867-877	☐
	VX	McCLUSKIE, et al. "The role of CpG in DNA vaccines", *Springer Semin Immunopathol* (2000) 22(1-2):125-132	☐
	VY	McGHEE, et al. "The mucosal immune system: from fundamental concepts to vaccine development", *Vaccine* (1992) 10(2):75-88	☐
	VZ	McHUTCHISON, et al. "Early viral response to CpG 10101, in combination with pegylated interferon and/or ribavirin, in chronic HCV genotype 1 infected patients with prior relapse response", *41st Annual Meeting of European Association for the Study of the Liver (EASL)* (2006) April 26-30, Vienna, Austria, submitted Abstract	☐
	WA	McHUTCHISON, et al. "Final results of a multi-center phase 1B, randomized, placebo-controlled, dose escalation trial of CpG 10101 in patients with chronic hepatitis C virus", *41st Annual Meeting of European Association for the Study of the Liver (EASL)* (2006) April 30, Vienna, Austria, presented Abstract #111	☐
	WB	McHUTCHISON, et al. "Early clinical results with CpG 10101, a new investigational antiviral TLT9 agonist being developed for treatment of subjects chronically infected with hepatitis C virus", *12th International Symposium on Viral Hepatitis and Liver Disease (ISVHLD)* (2006) July 3, Paris, France; presented Abstract #O105	☐
	WC	McIntyre, K., et al. "A sense phosphorothioate oligonucleotide directed to the initiation codon of transcription factor NF-kappa B p65 causes sequence-specific immune stimulation", *Antisense Res Dev* (1993) 3(4):309-322	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/621,254
				Filing Date	July 14, 2003
				First Named Inventor	Dow, Steven W.
				Art Unit	1643
(Use as many sheets as necessary)				Examiner Name	HOLLERAN, Anne L.
Sheet	36	of	48	Attorney Docket Number	021819-000300US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	WD	MESSINA, J.P., et al. "Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA", *J. Immunol.* (1991) 147(6):1759-1764	☐
	WE	MESSINA, J.P., et al. "The influence of DNA structure on the *in vitro* stimulation of murine lymphocytes by natural and synthetic polynucleotide antigens", *Cell Immunol.* (1993) 147(1):148-157	☐
	WF	MICONNET, et al. "CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide", *J Immunol* (2002) 168(3):1212-1218	☐
	WG	MILAS, et al. "CpG oligodeoxynucleotide enhances tumor response to radiation", *Cancer Res.* (2004) 64(15):5074-5077	☐
	WH	MOJCIK, C.F., et al. "Administration of a phosphorothioate oligonucleotide antisense to murine endogenous retroviral MCF *env* causes immune effects *in vivo* in a sequence-specific manner", *Clinical Immunology and Immunpathology* (1993) 67:130-136	☐
	WI	MOTTRAM, et al. "A novel CDC2-related protein kinase from leishmania mexicana, LmmCRK1, is post-translationally regulated during the life cycle", *J. Biol.Chem.* (1993) 268:28 21044-21052	☐
	WJ	MUHLHAUSER, et al. "VEGF165 expressed by a replication-deficient recombinant adenovirus vector induces angiogenesis in vivo", *Circ Res.* (1995) 77(6):1077-1086	☐
	WK	MUI, et al. "Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles", *J Pharmacol Exp Ther.* (2001) 298(3):1185-1192	☐
	WL	MUTWIRI, et al. "Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides", *J. Control Release* (2004) 97(1):1-17	☐
	WM	New England Biolabs 1993/94 Catalog, pp. 87-89 and 95 (1993)	☐
	WN	NIELSEN, et al. "Peptide nucleic acid (PNA). A DNA mimic with a peptide backbone", *Bioconjug Chem.* (1994) 5(1):3-7	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/621,254
				Filing Date	July 14, 2003
				First Named Inventor	Dow, Steven W.
				Art Unit	1643
(Use as many sheets as necessary)				Examiner Name	HOLLERAN, Anne L.
Sheet	37	of	48	Attorney Docket Number	021819-000300US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	WO	NORMAN, et al. "Liposome-mediated, nonviral gene transfer induces a systemic inflammatory response which can exacerbate pre-existing inflammation", *Gene Ther.* (2000) 7:1425-1430	☐
	WP	NYCE, J., et al. "DNA antisense therapy for asthma in an animal model", *Nature* (1997) 385:721-725	☐
	WQ	OCHIAI, et al. "Studies on lymphocyte subsets of regional lymph nodes after endoscopic injection of biological response modifiers in gastric cancer patients", *Int J Immunotherapy* (1986) 11(4):259-265	☐
	WR	Official Action for US Serial No. 08/386,063, filed Feb. 7, 1995, mailed March 12, 1999	☐
	WS	OKADA, et al. "Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms", *Int J Cancer* (1998) 78(2):196-201	☐
	WT	PAL, et al. "Immunization with Chlamydia trachomatis mouse pneumonitis major outer membrane protein by use of CpG oligodeoxynucleotides as an adjuvant induces a protective immune response against an intranasal chlmaydial challenge", *Infect Immun* (2002) 70(90):4812-4817	☐
	WU	PAVLICK, et al. "Novel therapeutic agents under investigation for malignant melanoma", *Expert Opin Investig Drugs* (2003) 12(9):1545-1548	☐
	WV	PAYETTE, et al. "History of vaccines and positioning of current trends", *Curr Drug Targets Infect Disord.* (2001) 1(3):241-247	☐
	WW	PERLAKY, et al. "Growth inhibition of human tumor cell lines by antisense oligonucleotides designed to inhibit p120 expression", *Anticancer Drug Des.* (1993) 8(1):3-14	☐
	WX	PISETSKY, D.S., et al. "Stimulation of *in vitro* proliferation of murine lymphocytes by synthetic oligodeoxynucleotides", *Molecular Biolology Reports* (1993) 18(3):217-221	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/621,254
				Filing Date	July 14, 2003
				First Named Inventor	Dow, Steven W.
				Art Unit	1643
(Use as many sheets as necessary)				Examiner Name	HOLLERAN, Anne L.
Sheet	38	of	48	Attorney Docket Number	021819-000300US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	WY	PISETSKY, D.S., et al. "Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus", *Life Science* (1994) 54(2):101-107	☐
	WZ	PISETSKY, D.S., et al. "Immunological properties of bacterial DNA", *Ann N Y Acad Sci* (1995) 772:152-163	☐
	XA	PISETSKY, D.S., et al. "Immunologic consequences of nucleic acid therapy", *Antisense Res Dev.* (1995) 5(3):219-225	☐
	XB	PISETSKY, et al. "The influence of base sequence on the immunological properties of defined oligonucleotides", *Immunopharmacology* (1998) 40(3):199-208	☐
	XC	PISETSKY, et al. "The influence of base sequence on the immunostimulatory properties of DNA", *Immunol Res.* (1999) 19(1):35-46	☐
	XD	PISETSKY, et al. "Influence of backbone chemistry on immune activation by synthetic oligonucleotides", *Biochem Pharmacol* (1999) 58(12):1981-1988	☐
	XE	POLANCZYK, et al. "Immunostimulatory effects of DNA and CpG motifs", *Cent Eur J of Immunol.* (2000) 25(3):160-166	☐
	XF	Promega Catalog 1993/94, P. 90 (1993)	☐
	XG	QUDDUS, J., et al. "Treating activated CD4+ T cells with either of two distinct DNA methyltransferase inhibitors, 5-azacytidine or procainamide, is sufficient to cause a lupus-like disease in sygeneic mice", *J Clin Invest* (1993) 92(1):38-53	☐
	XH	RAGHAVAN, et al. "Orally administered CpG oligodeoxynucleotide induces production of CXC and CC chemokines in the gastric mucosa and suppresses bacterial colonization in a mouse model of Helicobacter pylori infection", *Infect Immun.* (2003) 71(12):7014-7022	☐
	XI	RANKIN, et al. "CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved", *Antisense Nucleic Acid Drug Dev* (2001) 11(5):333-340	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/621,254
				Filing Date	July 14, 2003
				First Named Inventor	Dow, Steven W.
				Art Unit	1643
(Use as many sheets as necessary)				Examiner Name	HOLLERAN, Anne L.
Sheet	39	of	48	Attorney Docket Number	021819-000300US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	XJ	RATAJCZAK, et al. "In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides", *Proc Natl Acad Sci USA* (1992) 89(24):11823-11827	☐
	XK	RAZ, et al. *Proc Natl Acad Sci USA* (1994) 91:9519-9523	☐
	XL	RAZ, *Proc Natl Acad Sci USA* (1996) 93:5141-5145	☐
	XM	RAZ, et al. "Potential role of immunostimulatory DNA sequences (ISS) in genetic immunization and autoimmunity" *ACR Post Session C: Cytokines and Inflammatory Mediators* (1996), Abstract 615	☐
	XN	REDDY, et al. "Design of synthetic immunostimulatory motifs as agonists of Toll-like receptor 9: Use of N3-methyl-dC and N1-methyl-dG", 231st ACS National Meeting, Atlanta, GA, US. March 26-30, 2006 Meeting Abstract	☐
	XO	REITZ, et al. "Small-molecule immunostimulants. Synthesis and activity of 7,8-disubstituted guanosines and structurally related compounds", *J Med Chem.* (1994) 37(21):3561-3578	☐
	XP	Ren jun, et al. HCAPLUSs Database, AN: 198874, Abstract. 1994	☐
	XQ	REVAZ, et al. "The importance of mucosal immunity in defense against epithelial cancers", *Curr Opin Immunol* (2005) 17(2):175-179	☐
	XR	ROBERTSON, et al. "Crohn's trial shows the pros of antisense", *Nat Biotechnol* (1997) 15(3):209	☐
	XS	RODGERS, et al. "Effects of acute administration of O,S,S-trimethyl phosphorodithioate on the generation of cellular and humoral immune responses following in vitro stimulation", *Toxicology* (1988) 51(2-3):241-253	☐
	XT	ROJANASAKUL, Y. "Antisense oligonucleotide therapeutics: drug delivery and targeting", *Advanced Drug Delivery Reviews* (1996) 18:115-131	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/621,254
				Filing Date	July 14, 2003
				First Named Inventor	Dow, Steven W.
				Art Unit	1643
(Use as many sheets as necessary)				Examiner Name	HOLLERAN, Anne L.
Sheet	40	of	48	Attorney Docket Number	021819-000300US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	XU	ROTHENFUSSER, et al. "Recent advances in immunostimulatory CpG oligonucleotides", *Curr Opin Mol Ther.* (2003) 5(2):98-106	☐
	XV	RUDGINSKY, et al. "Antitumor activity of cationic lipid complexed with immunostimulatory DNA" *Mol Ther.* (2001) 4(4):347-355	☐
	XW	RYNKIEWICZ, et al. "Marked enhancement of antibody response to anthrax vaccine adsorbed with CPT 7909 in healthy volunteers", *45th Intersci. Conf. Antimicrob. Agents Chemother.* (2005 Sept. 21-24); New Orleans, Louisiana. Meeting Poster	☐
	XX	SAJIC,et al. "Parameters of CpG oligodoexynucleotide-induced protection against intravaginal HSV-2 challenge", *J Med Virol* (2003) 71(4):561-568	☐
	XY	SANDS, et al. "Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate", *Mol Pharmacol.* (1994) 45(5):932-943	☐
	XZ	SATOH, et al. "The study of mechanisms in CpG oligodoxynucleotides-induced aggravation in murine allergic contact dermatitis to 2.4-dinitrofluorobenzene", *Fukushima Igaku Zasshi* (2002) 52(3):237-250. Abstract	☐
	YA	SCHMIDT, et al. "Cytokine and Ig-production by CG-containing sequences with phosphorodiester backbone and dumbbell-shape", *Allergy* (2006) 61(1):56-63	☐
	YB	SCHNELL, et al. "Identification and characterization of a *Sac-charomyces cerevisiae* gene (PAR1) conferring resistance to iron chelators", *Eur. J. Biochem.* 200:487-493	☐
	YC	SCHWARTZ, D.A. et al. "CpG motifs in bacterial DNA cause inflammation in the lower respiratory tract", *J Clin Invest* (1997) 100(1):68-73	☐
	YD	SCHWARTZ, et al. "Bacterial DNA or oligonucleotides containing unmethylated CpG motifs can minimize lipopolysaccharide-induced inflammation in the lower respiratory tract through an IL-12-dependent pathway", *J Immunol.* (1999) 63(1):224-231	☐
	YE	SEDEGAH, et al. "Interleukin 12 induction of interferon gamma-dependent protection against malaria", *Proc natl Acad Sci USA* (1994) 91(22):10700-2	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/621,254
				Filing Date	July 14, 2003
				First Named Inventor	Dow, Steven W.
				Art Unit	1643
(Use as many sheets as necessary)				Examiner Name	HOLLERAN, Anne L.
Sheet	41	of	48	Attorney Docket Number	021819-000300US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	YF	SEMPLE, et al. "Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic acid", *J Pharmacol Exp Ther* (2005) 312(3):1020-1026 (Epub 2004 Nov. 3)	☐
	YG	SESTER, et al. "Phosphorothioate backbone modification modulates macrophage activation by CpG DNA", *J Immunol.* (2000) 165(8):4165-4173	☐
	YH	SHCHEPINOV, et al. "Oligonucleotide dendrimers: From poly-labelled DNA probes to stable nano-structures. Glen Research Glen Report located at <http://www.glenresearch.com/glenreports/GR12-11.html>, visited on March 3, 2006, 7 pages	☐
	YI	SHCHEPINOV, et al. "Oligonucleotide dendrimers: stable nano-structures", *Nucleic Acids Res.* (1999) 27(15):3035-3041	☐
	YJ	SHIRAKAWA T., et al. "The inverse association between tuberculin responses and atopic disorder", *Science* (1997) 275(5296):77-79	☐
	YK	SIDMAN, et al. "Gamma-interferon is one of several direct B cell-maturing lymphokines", *Nature* (1984) 309(5971):801-804	☐
	YL	SINGH, et al. "Cationic microparticles are an effective delivery system for stimulatory CpG DNA", *Pharm Res.* (2001) 18(10):1476-1479	☐
	YM	SJOLANDER,et al. "Kinetics, localization and isotype profile of antibody responses to immune stimulating complexes (iscoms) containing human influenza virus envelope glycoporteins", *Scand J Immunol.* (1996) 43(2):164-172	☐
	YN	SONEHARA, et al. "Hexamer palindromic oligonucleotides with 5'-CG-3' motif(s) induce production of interferon", *J Interferon Cytokine Res.* (1996) 16(10):799-803	☐
	YO	SPARWASSER, et al. "Bacterial DNA causes septic shock", *Nature* (1997) 386(6623):336-337	☐
	YP	SPARWASSER, et al. "Immunostimulatory CpG-oligodeoxynucleotides cause extramedullary murine hemopoiesis", *J Immunol* (1999) 162(4):2368-2374	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/621,254
				Filing Date	July 14, 2003
				First Named Inventor	Dow, Steven W.
				Art Unit	1643
(Use as many sheets as necessary)				Examiner Name	HOLLERAN, Anne L.
Sheet	42	of	48	Attorney Docket Number	021819-000300US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	YQ	SPARWASSER, et al. "Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor-alpha-mediated shock", *Eur J Immunol.* (1997) 27(7):1671-1679	☐
	YR	STEIN, et al. "Physicochemcial properties of phosphorothioate oligodeoxynucleotides", *Nucleic Acids Res.* (1988) 16(8):3209-3221	☐
	YS	STEIN, et al. "Oligodeoxynucleotides as inhibitors of gene expression: a review", *Cancer Research* (1988) 48:2659-2668	☐
	YT	STEIN, C.A., et al. "Antisense oligonucleotides as therapeutic agents - is the bullet really magical", *Science* (1993) 261:1004-1012	☐
	YU	STEIN, et al. "Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides", *Antisense Res Dev.* (1994) 4(2):67-69	☐
	YV	STEIN, et al. "Non-antisense effects of oligodeoxynucleotides", *Antisense Technology* (1997) ch 11:241-264	☐
	YW	STIRCHAK, et al. "Uncharged stereoregular nucleic acid analogs: 2. Morpholino nucleoside oligomers with carbamate internucleoside linkages", *Nucleic Acids Res.* (1989) 17(15):6129-6141	☐
	YX	STULL, et al. "Antigene, Ribozyme, and Aptamer Nucleic Acid Drugs: Progress and Prospects", *Pharmaceutical Res.* (1995) 12(4):465-483	☐
	YY	STUNZ, et al. "Inhibitory oligonucleotides specifically block effects of stimulatory CpG oligonucleotides in B cells", *Eur J Immunology* (2002) 32(5):1212-1222	☐
	YZ	SUBRAMANIAN, et al. "Theoretical Considerations on the 'Spine of Hydration' in the Minor Groove of d(CGCGAATTCGCG) d(CGGCTTAAGCGC): Monte Carlo Computer Simulation", *Proc Natl Acad Sci USA* (1988) 85:1836-1840	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/621,254
				Filing Date	July 14, 2003
				First Named Inventor	Dow, Steven W.
				Art Unit	1643
(Use as many sheets as necessary)				Examiner Name	HOLLERAN, Anne L.
Sheet	43	of	48	Attorney Docket Number	021819-000300US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	ZA	SUN, et al. "Type I interferon-mediated stimulation of T cells by CpG DNA", *J Exp Med.* (1998) 188(12):2335-2342	☐
	ZB	SUN, et al. "Multiple effects of immunostimulatory DNA on T cells and the role of type I interferons", *Springer Semin Immunopathol.* (2000) 22(1-2):77-84	☐
	ZC	SUZUKI, et al. "Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity", *Cancer Res* (2004) 64(23):8754-8760	☐
	ZD	SUZUKI, et al. "Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity", *Cancer Res* (2004) 64(23):8754-8760	☐
	ZE	TACKET, et al. "Phase I safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device", *Vaccine* (1999) 17(22):2826-2829	☐
	ZF	TAKATSUKI, et al. "Interleukin 6 perfusion stimulates reconstitution of the immune and hematopoietic systems after 5-fluorouracil treatment", *Cancer Res* (1990) 50(10):2885-2890	☐
	ZG	TAM, et al. "Liposomal encapsulation enhances the activity of immunostimulatory oligonucleotides", *Future Lipidology* (2006) 1(1):35-46	☐
	ZH	TANAKA, T., et al. "An antisense oligonucleotide complementary to a sequence in Iγ2b increases γ2b germline transcripts, stimulates B cell DNA synthesis, and inhibits immunoglobulin secretion", *J. Exp. Med.* (1992) 175:597-607	☐
	ZI	TARKÖY, et al, "Nucleic-Acid Analogues with Constraint Conformational Flexibility in the Sugar-Phosphate Backbone ('Bicyclo-DNA'). Part I. Preparation of (3S,5'R)-2'-Deoxy-3,5'-ethano-αβ-D-ribonucleosides ('Bicyclonucleosides')", *Helv Chim Acta* (1993) 76(1):481-510	☐
	ZJ	THREADGILL, et al. "Mitogenic synthetic polynucleotides suppress the antibody response to a bacterial polysaccharide", *Vaccine* (1998) 16(1):76-82	☐
	ZK	TOKUNAGA, et al. "A Synthetic Single-Stranded DNA, Ply (dG, dC), Induces Interferon α/β and -γ, Augments Natural Killer Activity and Suppresses Tumor Growth", *Jpn. J. Cancer Res.* (1988) 79:682-686	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/621,254
				Filing Date	July 14, 2003
				First Named Inventor	Dow, Steven W.
				Art Unit	1643
(Use as many sheets as necessary)				Examiner Name	HOLLERAN, Anne L.
Sheet	44	of	48	Attorney Docket Number	021819-000300US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	ZL	TOKUNAGA, et al. "Synthetic Oligonucleotides with Particular Base Sequence from the cDNA Encoding Proteins of *Mycobacterium bovis* BCG Induce Interferons and Activate Natural Killer Cells", *Microbiol. Immunol.* (1992) 36(1):55-66	☐
	ZM	TOKUNAGA, et al. "Response of the organism to DNA - With a focus on immunostimulatory DNA", *Kansen-Ensho-Meneki* (2001) 31(3):1-12	☐
	ZN	UHLMANN, et al. "Antisense Oligonucleotides: A New Therapeutic Principle", *Chemical Reviews* (1990) 90:543-584	☐
	ZO	UHLMANN, et al. "Recent advances in the development of immunostimulatory oligonucleotides", *Curr Opin Drug Discov Devel.* (2003) 6(2):204-217	☐
	ZP	VANENDRIESSCHE, et al. "Acyclic oligonucleotides: possibilities and limitations", *Tetrahedron* (1993) 49(33):7223-7238	☐
	ZQ	VERTHELYI, et al. "Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs", *J Immunol.* (2001) 166(4):2372-2377	☐
	ZR	VERTHELYI, et al. "Immunoregulatory activity of CpG oligonucleotides in humans and honhuman primates", *Clin Immunol.* (2003) 109(1):64-71	☐
	ZS	VICARI, et al. "Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody", *J Exp Med.* (2002) 196(4):541-549	☐
	ZT	VLASSOV, et al. "In Vivo pharmocokinetics of oligonucleotides following administration by different routes", CRC Press, Inc. Chapter 5 (1995) pp. 71-83	☐
	ZU	VOLLMER, et al. "Highly immunostimulatory CpG-free oligodeoxynucleotides for activation of human leukocytes", *Antisense Nucleic Acid Drug Dev.* (2002) 12(3):165-175	☐
	ZV	VOLLMER, et al. "Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities", *Eur J Immunol* (2004) 34(1):251-262	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/621,254
				Filing Date	July 14, 2003
				First Named Inventor	Dow, Steven W.
				Art Unit	1643
(Use as many sheets as necessary)				Examiner Name	HOLLERAN, Anne L.
Sheet	45	of	48	Attorney Docket Number	021819-000300US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	ZW	VOLLMER, et al. "Modulation of CpG oligodeoxynucleotide-mediated immune stimulation by locked nucleic acid (LNA)", *Oligonucleotides* (2004) 14(1):23-31	☐
	ZX	WAAG, et al. "Injection of inactivated phase I Coxiella burnetii increases non-specific resistance to infection and stimulates lymphokine production in mice", *Ann N Y Acad Sci* (1990) 590:203-214	☐
	ZY	WAGNER, "Gene inhibition using antisense oligodeoxynucleotides", *Nature* (1994) 372:L333-335	☐
	ZZ	WAGNER, "Interactions between bacterial CpG-DNA and TLR9 bridge innate and adaptive immunity", *Curr Opin Microbiol.* (2002) 5(1):62-69	☐
	AAA	WAGNER, et al. "CpG motifs are efficient adjuvants for genetic vaccines to induce antigen-specific protective anti-tumor T cell responses", 2000;203:429. Abstract R46	☐
	AAB	WALLACE, et al. "Oligonucleotide probes for the screening of recombinant DNA libraries", *Methods in Enzymology* (1987) 152:432-442	☐
	AAC	WANG, et al. "CpG oligodeoxynucleotides inhibit tumor growth and reverse the immunosupression caused by the therapy with 5-fluorouracil in murine hepatoma", *World J Gastroenterol* (2005) 11(8):1220-1224	☐
	AAD	WEERANTA, et al. "Reduction of Antigene Expression from DNA Vaccines by coadministered Oligodeoxynucleotides", *Antisense and Nucleic Acid Drug Development* (1998) 8:351-356	☐
	AAE	WEERATNA, et al. "CpG ODN can redirect the Th bias of established Th2 immune responses in adult and young mice", *FEMS Immunol Med Microbiol* (2001) 32(1):65-71	☐
	AAF	WEERATNA, et al. "CpG DNA induces stronger immune responses with less toxicity than other adjuvants", *Vaccine* (2000) 18(17):1755-1762	☐
	AAG	WEINER, et al. "Immunostimulatory CpG oligodeoxynucleotide is effective as an adjuvant in inducing production of anti-idiotype antibody and is synergistic with GMCSF", *Blood* (1996) 88(10):Suppl. 1 pt. 1. Abstract #348	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/621,254
				Filing Date	July 14, 2003
				First Named Inventor	Dow, Steven W.
				Art Unit	1643
(Use as many sheets as necessary)				Examiner Name	HOLLERAN, Anne L.
Sheet	46	of	48	Attorney Docket Number	021819-000300US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	AAH	WEINER, et al. "The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides", *J Leukoc Biol.* (2000) 68(4):455-463	☐
	AAI	WEISS, R. "Upping the Antisense Ante: Scientists bet on profits from reverse genetics", *Science* (1991) 139:108-109	☐
	AAJ	WERNETTE, et al. "CpG oligodeoxynucleotides stimulate canine and feline immune cell proliferation", *Vet Immunol Immunopathol.* (2002) 84(3-4):223-236	☐
	AAK	WHALEN, R., "DNA vaccines for emerging infection diseases: What If?", *Emerging Infectious Disease* (1996) 2(3):168-175	☐
	AAL	WHITESELL, et al. "Stability, clearance, and disposition of intraventricularly administered oligodeoxynucleotides: implications for therapeutic application within the central nervous system", *Proc Natl Acad Sci USA* (1993) 90(10):4665-4669	☐
	AAM	WHITMORE, et al. "LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth", *Gene Ther.* (1999) 6:1867-1875	☐
	AAN	WHITMORE, et al. "Systemic administration of LPD prepared with CpG oligonucleotides inhibits the growth of established pulmonary metastases by stimulating innate and acquired antitumor immune responses", *Canc Immun Immunother.* (2001) 50:503-514	☐
	AAO	WOOLDRIDGE, et al. "Select unmethylated CpG oligodeoxynucleotide improve antibody dependent cellular cytotoxicity in vitro and in vivo", *Proc Am Assoc Cancer Res* (1996) 37(3253):477	☐
	AAP	WOOLDRIDGE, et al. "Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma", *Blood* (1997) 89(8):2994-2998	☐
	AAQ	WU, G.Y., et al. "Receptor-mediated gene delivery and expression in vivo", *J. Biological Chemistry* (1988) 263:14621-14624	☐
	AAR	WU-PONG, S. "Oligonucleotides: Opportunities for Drug Therapy and Research", *Pharmaceutical Technology* (1994) 18:102-114	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/621,254
				Filing Date	July 14, 2003
				First Named Inventor	Dow, Steven W.
				Art Unit	1643
(Use as many sheets as necessary)				Examiner Name	HOLLERAN, Anne L.
Sheet	47	of	48	Attorney Docket Number	021819-000300US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	AAS	YAMAMOTO, S., et al. "In vitro augmentation of natural killer cell activity and production of interferon-alpha/beta and-gamma with deoxyribonucleic acid fraction from *Mycobacterium bovis* BCG", *Jpn J Cancer Res* (1988) 79:866-873	☐
	AAT	YAMAMOTO, S., et al. "Unique palindromic sequences in synthetic oligonucleotides are required to induce INF and augment INF-mediated natural killer activity", *The Journal of Immunology* (1992) 148:4072-4076	☐
	AAU	YAMAMOTO, S., et al. "DNA from Bacteria, but Not from Vertebrates, Induces Interferons, Activates Natural Killer Cells and Inhibits Tumor Growth", *Microbiol. Immunol.* (1992) 36(9):993-997	☐
	AAV	YAMAMOTO, S., et al. "Mode of Action of Oligonucleotide Fraction Extracted From *Mycobacterium bovis* BCG", *Kekkaku* (1994) 69(9):29-32	☐
	AAW	YAMAMOTO, T., et al. "Ability of oligonucleotides with certain palindromes to induce interferon production and augment natural killer cell activity is associated with their base length", *Antisense Research and Development* (1994) 4:119-123	☐
	AAX	YAMAMOTO, T., et al. "Synthetic Oligonucleotides with Certain Palindromes Stimulate Interferon Production of Human Peripheral Blood Lymphocytes in vitro", *Jpn J. Cancer Res* (1994) 85:775-779.	☐
	AAY	YAMAMOTO, T., et al. "Cytokine production inducing action of oligo DNA", *Rinsho Meneki* (1997) 29(2):1178-1184	☐
	AAZ	YI, et al. "Rapid immune activation by CpG motifs in bacterial DNA. Systemic induction of IL-6 transcription through an antioxidant-sensitive pathway", *J Immunol* (1996) 157(12):5394-5402	☐
	BBA	YI, et al. "IFN-γ promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligodeoxynucleotides", *J Immunol.* (1996) 1546(2):558-564	☐
	BBB	YI, et al. "Rapid induction of mitogen-activated protein kinases by immune stimulatory CpG DNA", *J Immunol.* (1998) 161(9):4493-4497	☐
	BBC	YI, et al. "CpG oligodeoxyribonucletides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry", *J Immunol.* (1998) 160(12):5898-5906	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				*Application Number*	10/621,254
				Filing Date	July 14, 2003
				First Named Inventor	Dow, Steven W.
				Art Unit	1643
(Use as many sheets as necessary)				*Examiner Name*	HOLLERAN, Anne L.
Sheet	48	of	48	*Attorney Docket Number*	021819-000300US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	BBD	YU, et al. "Accessible 5'-end of CpG-containing phosphorothioate oligodeoxynucleotides is essential for immunostimulatory activity", *Bioorg Med Chem Lett* (2000) 10(23):2585-2588	☐
	BBE	YU, et al. "Modulation of immunostimulatory activity of CpG oligonucleotides by site-specific deletion of nucleobases", *Bioorg Med Chem Lett.* (2001) 11(17):2263-2267	☐
	BBF	ZHAO, Q., et al. "Stage-specific oligonucleotide uptake in murine bone marrow B-cell precursors", *Blood* (1994) 84(11):3660-3666	☐
	BBG	ZHAO, et al. "Modulation of oligonucleotide-induced immune stimulation by cyclodextrin analogs", *Biochem Pharmacol* (1996) 52(10):1537-1544	☐
	BBH	ZHAO, et al. "Effect of different chemically modified oligodeoxynucleotides on immune stimulation", *Biochem Pharmacol* (1996) 51(2):173-182	☐
	BBI	ZHAO, et al. "Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice", *Antisense Nucleic Acid Drug Dev.* (1997) 7(5):495-502	☐
	BBJ	ZHAO, et al. "Site of chemical modifications in CpG containing phosphorothioate oligodeoxynucleotide modulates its immunostimulatory activity", *Bioorg Med Chem Lett* (1999) 9(24):3453-3458	☐
	BBK	ZHAO, et al. "Immunostimulatory activity of CpG containing phosphorothioate oligodeoxynucleotide is modulated by modification of a single deoxynucleoside", *Bioorg Med Chem Lett.* (2000) 10(10):1051-1054. Abstract Only	☐
	BBL	ZHU, et al. "Modulation of ovalbumin-induced Th2 responses by second generation immunomodulatory oligonucleotides in mice", *Int Immunopharmacol* (2004) 4(7):851-862	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.